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ABSTRACT 
 
INTRODUCTION 
The focus of this MD thesis has been relaxin, a member of the insulin family, 
which is a protein composed of two disulphide linked chains of approximately 
6000  Daltons.      Relaxin  has  been  traditionally  recognised  as  a  hormone  of 
parturition,  though  more  recently  it  has  been  postulated  that  relaxin  may  be 
involved  in  cardiovascular  regulation.  We  used  concentrations  similar  to  those 
found  in  the  plasma  in  physiological  (non-pregnant,  pregnancy)  and 
pathophysiological  (chronic  heart  failure)  states.  Firstly,  we  characterised  the 
effects of relaxin in small human resistance arteries ex vivo using wire myography 
obtained  from  gluteal  biopsies  taken  from  patients  with  coronary  heart  disease 
(CHD) and normal left ventricular systolic function.  We also studied the same 
effects in larger calibre arteries (internal mammary) and veins (saphenous) using 
standard organ bath techniques.
  The effect of relaxin in veins has not previously 
been  described.  Internal  mammary  arteries  and  saphenous  veins  were  obtained 
from patients undergoing coronary artery bypass surgery. Small pulmonary arteries 
were obtained from patients undergoing thoracotomy for bronchial carcinoma. In 
addition, we wished to determine if a transcardiac or transpulmonary gradient of 
relaxin  could  be  measured  to  suggest  either  pulmonary  or  cardiac  secretion  or 
clearance of the hormone. Relaxin secretion in heart failure has previously been 
described. Lastly, we wished to determine whether an increased relaxin plasma 
concentration  in  patients  with  chronic  heart  failure  (CHF),  is  of  prognostic 
importance. 
 
METHODS AND RESULTS 
i)comparative potency of relaxin compared to other vasodilators:  Small resistance 
arteries were obtained from biopsies taken from patients with CHD. Each set of 
vessels was preconstricted with noradrenaline. Thereafter, cumulative concentration 
response  (relaxation)  curves  (CRCs)  were  constructed  with  known  vasodilators   25 
atrial  natriuretic  peptide  (ANP),  epoprostenol,  substance  P  and  relaxin  (n=8). 
Relaxin was found to be a more potent vasodilator than ANP and equipotent to 
epoprostenol.  
ii) mechanism of vasorelaxation: CRCs to relaxin (as above) were constructed to 
identify  the  importance  of  the  endothelium  –  following  the  removal  of  the 
endothelium by the established method of intraluminal rubbing with a human hair. 
We found that relaxin is endothelium dependent.  
iii)  interaction  of  relaxin  with  nitric  oxide  and  other  possible  mechanisms  of 
vasodilation  and  importance  of  ACE  inhibitor  treatment:  We  identified  the 
importance of the  effect of ACE inhibitor treatment on the  action of relaxin in 
human resistance arteries. Relaxin’s vasodilatory action was significantly reduced 
in those patients on ACE inhibitors (n=28) compared with those patients not on 
ACE inhibitors (n=30). In patients treated with an ACE inhibitor, we found that 
manipulation  of  prostanoids  is  important.  Indomethacin,  (a  cyclooxygenase 
inhibitor) (n=8) blocked relaxin’s vasodilatory action. Manipulation of the cAMP 
second messenger system, with milrinone, (a cAMP phosphodiesterase inhibitor) 
(n=6) is also important as relaxin’s vasodilatory action was enhanced. Manipulation 
of cyclic  GMP  second  messenger  system  is  also  important. ODQ,  (a  guanylate 
cyclase  inhibitor)  (n=10)  reduced  relaxin’s  action  while  zaprinast,  (a  cGMP 
phosphodiesterase  inhibitor)  (n=7)  enhanced  relaxin’s  action.    Manipulation  of 
nitric  oxide  with  L-NAME  (n=8)  and  L-NOARG  (n=10),  nitric  oxide  synthase 
(NOS) inhibitors and EDHF with apamin and charybdotoxin (potassium channel 
blockers) (n=7) had a curious effect causing the opposite action to that expected, by 
enhancing  relaxin’s  vasodilatory  action.  In  patients  not  treated  with  an  ACE 
inhibitor, we found that manipulation of nitric oxide with L-NAME (n=8) and L-
NOARG  (n=8),  is  important,  as  both  reduced  relaxin’s  vasodilatory  action. 
Manipulating the cGMP second messenger system with ODQ (n=8) greatly reduced 
relaxin’s action. but zaprinast (n=9) did not. Manipulation of EDHF with apamin 
and  charybdotoxin  (n=8)  had  no  effect  on  relaxin’s  action.  Manipulation  of 
prostanoids with indomethacin (n=10) reduced relaxin’s action but manipulation of 
cAMP with milrinone (n=8), had no effect.   26 
iv)relaxin  and  small  human  pulmonary  arteries:  We  determined,  using  wire 
myography, that relaxin is not a vasodilator of small pulmonary resistance arteries 
(n=5).  
v)relaxin and large calibre vessels: We determined, using the organ bath technique, 
that  relaxin  is  not a  vasodilator  of  larger  calibre  arteries  i.e.  internal  mammary 
arteries removed from patients during coronary artery bypass surgery (n=5).Relaxin 
is  not  a  venodilator  studying  saphenous  veins  removed  from  patients  during 
coronary artery bypass surgery (n=5). 
vi)transmyocardial  and  transpulmonary  gradient  of  relaxin:  Plasma  relaxin 
concentrations were measured using a validated assay. Samples were taken from 
patients  undergoing  CABG  surgery,  from  the  aorta,  coronary  sinus,  pulmonary 
artery  and  pulmonary  vein.  We  found  that  in  20  patients  with  normal  left 
ventricular  function  that  there  was  no  transpulmonary  gradient  but  there  was  a 
transcardiac gradient suggesting net cardiac extraction of relaxin.  
vii)prognostic value of relaxin in patients with chronic heart failure: Relaxin was 
compared  with  N-terminal  pro  brain  natriuretic  peptide  to  determine  whether 
relaxin is of prognostic importance. Plasma concentrations of the hormones were 
measured in 87 patients admitted with CHF. These patients were followed up for a 
year  during  which  time  hospitalisations  due  to  CHF  and  death  were  recorded. 
While  NT-proBNP  was  found  to  be  a  powerful  and  independent  predictor  of 
outcome in these patients, relaxin was not. 
 
CONCLUSION. 
In addition to its established role in pregnancy, relaxin has many other actions. In 
particular, its antihypertensive, antithrombotic and vasodilatory properties suggest 
that relaxin may have a central role in cardiovascular regulation.  
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CHAPTER 1: 
INTRODUCTION. 
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1.1 THE DISCOVERY OF RELAXIN. 
 
Relaxin, a peptide hormone, is a member of the insulin-like growth factor family 
with a molecular weight of 6000 daltons. It is made up of 53 amino acids with two 
disulfide-linked chains, A and B, with B bearing the receptor interaction site (Fig 
1). 
 
Structure of Relaxin 
 
(Adapted from Teichman et al, 2008). 
 
Discovered  in  1926  by  Frederick  Hisaw,  it  is  best  known  as  a  hormone  of 
parturition, responsible for structural remodeling of the birth canal. This effect is 
thought to reflect complex actions on reducing fibroblast collagen synthesis and 
enhancing collagen breakdown (Bani, 1997). Hisaw first reported on the relaxation 
of the interpubic ligament of female  guinea pigs following injections of serum 
from pregnant guinea pigs or rabbits (Hisaw, 1926). Four years later, Hisaw and   29 
his group (Fevold et al, 1930) obtained a crude aqueous extract from sow corpora 
lutea with chemical characteristics of a peptide and which retained the property to 
elongate the interpubic ligament. This substance was identified as a new hormone 
and was given the name “relaxin”. 
 
1.2 RELAXIN FAMILY PEPTIDES 
 
The relaxin family peptides are a sub-group of the relaxin- insulin peptide family. 
All peptides within this family have a uniform two chain structure, with two inter-
chain and one intra-chain disulphide bond. In the human, there are seven relaxin 
family  peptides:  the  human  gene  1  (H1-relaxin),  human  gene  2  (H2-relaxin, 
commonly referred to as relaxin and equivalent to other species’ relaxin-1) and 
human gene 3 (H3-relaxin), and the insulin/relaxin-like peptides INSL3, INSL4, 
INSL5 and INSL6. Currently only four of the peptides have identified receptors, 
although there is a degree of cross-reactivity between peptides and receptors. 
 
   
1.3 RELAXIN RECEPTORS. 
 
It was with great excitement within the world of relaxinologists in 2002, the news 
was  received  that  the  relaxin  receptors  had  now  been  identified.  Hsu  et  al, 
described two G-protein coupled receptors LGR7 (Leucine-rich repeat containing 
guanine nucleotide binding receptor 7) and LGR8 that mediate the action of relaxin   30 
through a cAMP dependent pathway (Hsu et al, 2002). They transfected cells with 
known G-protein coupled receptors with no known ligands. Treatment of these 
cells  with  porcine  relaxin  resulted  in  a  dose  dependent  increase  in  cAMP 
production. LGR7 and LGR8 were not affected by treatment with insulin or insulin 
growth factor I or II (despite these proteins having a similar domain arrangement to 
prorelaxin, the precursor of relaxin). As relaxin belongs to the group of peptide 
hormones  that  includes  insulin,  the  finding  that  relaxin receptors  are  G-protein 
coupled  receptors  rather  than  an  orphan  membrane-associated  tyrosine  kinase 
receptor resembling those that bind to insulin, is surprising.  
 
The expression pattern of these receptors was also examined. LGR7 was expressed 
in  the  brain,  kidney,  testis,  placenta,  uterus,  ovary,  adrenals, prostate,  skin  and 
heart whereas LGR8 was mainly present in brain, kidney, muscle, testis, thyroid, 
uterus, peripheral blood cells and bone marrow. The wide distribution of these 
relaxin receptors is in keeping with relaxin’s pleiotropic actions. 
 
Meanwhile, a group of investigators at the Howard Florey Institute in Australia, 
discovered relaxin-3. (Bathgate et al, 2002). An intriguing finding of relaxin-3 was 
its  nearly  exclusive  expression  in  the  brainstem.  Subsequent  searches  of  all 
available  genomes  using  the  relaxin-3  sequence  found  that  relaxin  is  not 
mammalian specific. Relaxin-3 sequences were found in fish species (zebrafish, 
fugufish and Tetraodon, a frog (Xenopus) and a chicken. Hsu et al demonstrated 
that relaxin-3 was capable of activating LGR7 relaxin receptor but not LGR8.    31 
The discovery that the orphan receptor LGR7 is the relaxin receptor was largely 
attributable to the pursuit of an idea raised by the combination of the similarity of 
the structure of LGR7 to LGR8 and the similarity of the structure of relaxin to 
INSL3 (gene encoding insulin-like peptide) (Hsu et al, 2002). LGR7 and LGR8, 
which are 757 (Hsu et al, 2002) and 737 (Overbeek et al, 2001) amino acids in 
length, respectively, share about 60% amino acid sequence identity and contain 10 
leucine-rich repeats in their large N-terminal extracellular domain. Two orphan G-
protein-coupled  receptors  designated  GPCR135  and  GPCR142  were  recently 
proposed as putative receptors for relaxin-3 (Liu et al, 2003a,b). Both receptors 
belong to the type I family of GPCRs. Unlike LGR7 and LGR8, GPCR135 and 
GPCR142 have short N-terminal extracellular domains, and they contain only 469 
and 374 amino acid residues, respectively. 
 
With the discovery of more relaxin receptors, it was decided by the International 
Union  of  Pharmacology  Committee  on  Receptor  Nomenclature  and  Drug 
Classification  (NC-IUPHAR),  established  in  1987,  that  the  nomenclature  for 
relaxin  receptors  should  be  examined  (Table  1.1).  Led  by  Professor  Summers, 
Professor  of  Pharmacology,  University  of  Monash,  Australia,  a  review  was 
published in 2006 with the revision of the nomenclature  for the relaxin family 
peptides and their receptors (Bathgate et al, 2006).  
 
Relaxin receptors have now been identified in many tissues including reproductive 
tissues,  cardiovascular  and  renal  systems  and  the  brain.  Table  1.2  provides  a   32 
summary of the distribution of human tissues where RXFP receptors 1 to 4 have 
been detected. 
 
 
 
Table 1.1.  Recommendations for the Nomenclature of Receptors for Relaxin 
Family Peptides 
 
 
 
 
 
 
 
 
 
RXFP = Relaxin Family Peptide Receptor 
LGR = Leucine-Rich Repeat Containing Guanine Nucleotide Binding Receptor 
GPCR = G-Protein-Coupled Receptor 
Adapted from Bathgate et al, 2006 
 
 
 
 
RECEPTOR  PREVIOUS NAME 
RXFP 1  LGR7 
RXFP 2  LGR8 
RXFP 3    GPCR135 
RXFP 4  GPCR142   33 
 
Table 1.2  Distribution of Receptors for Relaxin and Relaxin Related Peptides 
in Humans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*mRNA by Northern blot analysis, **protein by immunohistochemical analysis 
Adapted from Bathgate et al, 2006. 
Tissue  RXFP 1  RXFP 2  RXFP 3  RXFP 4 
Ovary  mRNA*      mRNA 
Uterus  mRNA  mRNA    mRNA 
Placenta  mRNA      mRNA 
Breast  protein**       
Testis  mRNA  mRNA  mRNA  mRNA 
Prostate  mRNA      mRNA 
Brain  mRNA  mRNA  mRNA  mRNA 
Pituitary      mRNA   
Kidney  mRNA  mRNA    mRNA 
Heart  mRNA      mRNA 
Lung  mRNA       
Liver  mRNA       
Muscle  mRNA  mRNA    mRNA 
Thyroid  mRNA  mRNA    mRNA 
Adrenal  mRNA    mRNA  mRNA 
Skin  mRNA         34 
RXFP1 and RXFP2 are both classified as type C LGRs. Figure 1.2 below is a 
schematic diagram of a type C LGR. 
These receptors have a large and distinctive ectodomain encompassing an LDL 
class A (LDLa) module at the extreme N-terminus followed by 10 LRR (leucine 
rich repeats), a unique hinge region leading into the transmembrane domain (seven 
transmembrane  helices)  and  an  intracellular  C-terminal  tail.  The  LDLa  module 
distinguishes RXFP1 and RXFP2 from other LGR receptors and other GPCRs. 
 
 
Figure 1.2 Relaxin Receptor. 
 
 
 
Adapted from van der Westhuizen et al, 2008 
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1.4 RELAXIN COMPARED WITH INSULIN. 
 
Relaxin was compared to insulin as early as 1930. Both porcine relaxin and insulin 
have a molecular weight of 6000 daltons and consist of two chains, a smaller A 
chain and a larger B chain. With the elucidation of the first primary structure of 
relaxin and the positive identification of the crosslink pattern, a direct comparison 
of the structures of these two hormones became possible. Surprisingly only a small 
number  of  amino  acids  are  identical  in  insulin  and  relaxin.  Six  of  the  eight 
identities are the cysteines from an insulin-like disulfide structure (Schwabe and 
McDonald,  1977),  and  two  additional  homologous  residues  are  the  structurally 
important glycines of the B chains (B11, B23). 
 
Amino acid residues forming the hydrophobic core of insulin are hydrophobic in 
relaxin as well and the helical segments localized in the N-terminal and C-terminal 
region of the A chain and the mid-region of the B chain of relaxin contain amino 
acids that would also be consistent with helical conformations. The three glycine 
residues  of  the  insulin  B  chain  allow  for  β-turn-formation,  and  since  the  two 
glycines in the relaxin B chain are homologous, two of the three β-turns may be 
expected to occur in relaxin. 
 
Although there is strong evidence that relaxin is structurally related to insulin there 
are  also  distinct  differences  in  terms  of  the  surface  properties  of  these  two 
hormones, i.e. all relaxins of known primary structure are basic proteins whereas   36 
insulins  are  generally  acidic  proteins.  In  spite  of  overall  structural  similarities 
between insulin and relaxin the primary sequences vary sufficiently to eliminate all 
antigenic and biological cross-reactivity (Schwabe and Bullesbach, 1990). 
 
 
1.5 RELAXIN IN OTHER ANIMALS. 
 
Soon after its discovery in the ovaries of guinea pigs, investigators became curious 
to establish how widely distributed relaxin is in the animal kingdom. (Schwabe and 
Bullesbach, 1990). Using the guinea pig relaxation assay, it has been possible to 
find out that relaxin is not only a hormone of viviparity in mammals. There have 
been reports of relaxin in shark and whale ovaries as well as rooster and armadillo 
testes.  Pregnant  bats  have  also  been  found  to  rely  on  relaxin  for  propagation. 
Detection of relaxin in these unusual places has been confirmed at least in part by 
isolation and sequence analysis. In the dog, relaxin persists after pregnancy during 
lactation.  Although the  source  of  relaxin  in  the  dog  is  not  known,  it has  been 
suggested  that  both  ovaries  and  the  placenta  might  be  a  site  of  synthesis. 
Postpartum persistence of relaxin during lactation and the discovery of an immuno-
reactive  relaxin-like  component  in  the  milk  of  Labrador  retrievers  suggest  the 
mammary gland as an additional source. (Steinetz et al, 1987).  
 
Preliminary reports of relaxin in protozoa have been described by Schwabe et al 
(Schwabe et al, 1983) and immunoreactive molecules have also been detected in   37 
prokaryotes  (Bacillus  subtilis)  and  even  in  lower  plants  (Spirogyra)  by 
radioimmunoassay (RIA) with sheep anti-porcine relaxin antibodies. Whilst these 
studies  are  in  need  of  confirmation,  similar  findings  have  been  reported  with 
insulin (LeRoith et al, 1980, 1981) which increases the likelihood that the genes 
for relaxin and insulin are present in unicellular life and in the plant kingdom. 
 
A plethora of relaxin functions has been proposed on the basis of physiological 
studies in a large variety of animals. The single most characteristic property of 
relaxin  appears  to  be  the  widening  of  the  birth  canal  in  mammals  prior  to 
parturition. However, the response of different components of the birth canal, vary 
to differing degrees in various species. For example, the symphysis pubis relaxes 
proportionately less in women than in mice, guinea pigs or bats. In humans, other 
parts of the pelvic girdle, such as the sacroiliac joint are also affected whereas in 
guinea pigs major remodeling occurs only in the symphysis pubis. 
 
 
1.6 THE PRODUCTION OF RELAXIN IN HUMANS. 
 
Relaxin is produced in the corpus luteum, placenta, prostate (in men) and the heart. 
In humans,  three  molecular  forms,  each  encoded  by  separate  genes,  have  been 
identified - H1, H2 and H3. H1 and H2 are found on chromosome 9 while H3 is 
found on chromosome 19. Only the H2 form circulates in plasma. In women, H2 is 
also expressed in the corpus luteum, endometrium, placenta and breast, while H1 is   38 
expressed only in the placenta.  In men, both H1 and H2 are expressed in the 
prostate gland. H3, which has only recently been identified, (Bathgate et al, 2002) 
is expressed in the brainstem.  Relaxin mRNA   H1 and H2 are expressed in human 
left ventricle, right atrium, the internal mammary artery and saphenous vein. 
 
 
1.6.1 In Health.  
 
Relaxin is produced in both pre- and post-menopausal women and also in men.  
The  highest  plasma  concentrations  are  attained  during  pregnancy  at  around  1-
2ng/ml,  when  relaxin  is  produced  mainly  by  the  corpus  luteum  and  also  the 
placenta. Relaxin can be found in peripheral blood in conception cycles by the time 
of missed menses and concentrations rapidly rise and peak by the middle of the 
first  trimester  of  pregnancy.  Serum  levels  then  fall  by  approximately  20%  and 
remain stable throughout pregnancy. (Weiss, 1991).  
 
As  previously  stated,  relaxin  prepares  the  birth  canal  for  delivery.  Initially 
however,  relaxin  increases  the  secretion  of  prostacyclins  which  decrease 
myometrial contractility. Later, relaxin ripens the human cervix at term therefore 
inducing labour and plays a part in the changes in pelvic diameter as demonstrated 
radiographically.with  pubic  symphysis  changes.  Elevated  first  trimester  relaxin 
levels  have  been  shown  to  be  associated  with  an  increased  risk  of  premature 
delivery (Weiss et al, 1993).    39 
 
Another  action  of  relaxin  during  pregnancy  is  on  glucose  metabolism.  Relaxin 
increases the affinity of insulin to its own receptor in isolated human adipocytes in 
vitro from women at term gestation. Thus it is possible that circulating relaxin may 
have  a  protective  effect  from  the  diabetogenetic  effects  of  pregnancy  (Weiss, 
1991). 
 
In non-pregnant women, relaxin is produced by the corpus luteum.  Levels during 
the menstrual cycle are highest after the luteinising hormone (LH) surge, around 
30-150 pg/ml. Since this is the period of nidation, a role for relaxin during this 
phase has been postulated.  
In men, relaxin is produced by the prostate gland. This is verified by taking semen 
samples that exclude testicular and seminal vesicle components, such as samples 
from men who have had a vasectomy or from men with congenital absence of the 
vas and seminal vesicles, where relaxin concentrations are undiminished. (Weiss, 
1991). This observation has been confirmed by the finding that in split ejaculates 
the first part of the ejaculate is richer in relaxin. The first part of the split ejaculate 
is  predominantly  prostatic,  whereas, the  second part  is  predominantly from  the 
seminal vesicles. (DeCooman  et al, 1983).  
 
It has been demonstrated that physiological concentrations of relaxin are effective 
in increasing sperm penetration into cervical mucus, which is the first barrier that 
sperm meets in traversing the female genital tract (Brenner et al, 1984). Relaxin   40 
also significantly increases the motility of sperm in situations of decreased motility 
i.e. when sperm motility is apparently optimal, as in normal samples, addition of 
relaxin  does  not  produce  a  further  increase  in  motility.  (Lessing  et  al,  1986). 
Relaxin secretion into seminal plasma by the male represents a novel physiological 
mechanism for hormone delivery. 
 
 
1.6.2 In Disease.  
 
Plasma relaxin concentrations are also increased in the pathophysiological states.  
The heart has been identified both as an additional source of relaxin and also as a 
target  for  this  hormone.    Specific  binding sites for  relaxin  have been found  in 
cardiac tissues, particularly the atria (Taylor et al, 1994), (Osheroff et al, 1992). 
Relaxin  has  been reported  to  increase  natriuretic  peptide  secretion  and  to  have 
positive chronotropic actions. (Toth et al, 1996) Of note, cardiac secretion and 
plasma concentrations of relaxin increase in heart failure and these increases are 
greatest in  those  patients  with  the  most  severe  degrees of  failure  (15-20pg/ml) 
(Dschietzig et al, 2001).
 This suggests that the heart may be producing relaxin as a 
“compensatory” or protective response, consistent with its role as an endocrine 
organ. This will be discussed in more detail later. 
 
Hocher et al, investigated the impact of relaxin on deaths in patients with end-stage 
kidney  disease  (ESKD).  Patients  with  ESKD  have  a  reduced  life  expectancy   41 
mainly as a result of cardiovascular disease. 245 patients (123 male) on long term 
haemodialysis were  followed up for 1140 days. Survival was compared by the 
Kaplan-Meier  method  and  Cox  regression  analysis.  Elevated  serum  relaxin 
concentrations (greater than median of 28.8 pg/ml) independently predicted all-
cause  and  cardiovascular  death  in  male  but  not  female  patients  (Hocher  et  al, 
2004).  
 
1.7 SECRETION OF RELAXIN. 
 
It  is  known  that  relaxin  is  produced  in  the  corpus  luteum.  Taylor  and  Clark 
examined whether prostacyclin may act as a secretagogue for relaxin release from 
cultured porcine luteal cells (Taylor and Clark, 1987). 
The release of relaxin from cultured porcine luteal cells (derived from pregnant 
sows) was detected by a reverse haemolytic plaque assay. In this assay, luteal cells 
are cocultured in monolayers with protein-A coupled ovine erythrocytes. In the 
presence of porcine relaxin antiserum and complement, a zone of haemolysis i.e. a 
plaque,  develops  around  relaxin-releasing  luteal  cells.  Treatment  with  a 
prostacyclin  analogue,  carba-prostacyclin,  significantly  accelerated  the  rate  of 
plaque formation in a dose dependent manner. This analogue, chemically stable in 
aqueous  medium,  exerts  potent  PGI-2-like  effects  both  in  vivo  and  in  vitro. 
Therefore, it appears that PGI-2 acts as a secretagogue for relaxin release from 
cultured porcine luteal cells.    42 
Taylor and Clark also studied what may act as a local inhibitory mechanism to 
regulate  relaxin  secretion  (Taylor  and  Clark,  1992).  They  examined  basic 
fibroblast growth factor (FGF) which is involved in the development and function 
of  the  corpus  luteum  and  has  been  shown  to  regulate  ovarian  steroidogenesis 
(Baird and Hsueh, 1986). Exposure of luteal cell-containing monolayers to basic 
FGF  resulted  in  a  significant  reduction  (p<0.05)  in  the  rate  of  relaxin-induced 
plaque formation. In addition, PGE-2-stimulated secretion of relaxin by porcine 
luteal cells was diminished by basic  FGF suggesting that there stimulatory and 
inhibitory agents acting to achieve fine control of relaxin secretion. 
 
1.8 VASCULAR ACTIONS OF RELAXIN. 
 
Before discussing the current literature on the vascular actions of relaxin, I will 
briefly describe the anatomy and physiology of blood vessels. 
 
1.8.1 Anatomy and Function of Blood Vessels  
 
Arteries have three layers: the intima, media and adventitia. The intima consists of 
the  vascular  endothelium,  which  is  a  single  layer  of  cells  and  a  thin  layer  of 
connective  tissue.  It is separated  from  the  media  by  the  internal  elastic  lamina 
made of elastin and fibrous tissue. The media consists of fibrous tissue, vascular 
smooth  muscle  and  elastin.  The  media  is  separated  from  the  adventitia  by  the   43 
external elastic lamina. The adventitia consists of collagen and fibrous tissue that 
forms loose connective tissue. 
 
The  connective  tissue  of  large  arteries  contains  more  elastin,  whereas  smaller 
arteries have more collagen. The elastic properties of healthy large arteries, such as 
the  ascending  aorta,  help  to  cushion  the  stroke  volume,  decrease  the  work  of 
ejection by the left ventricle and maintain pressure during diastole. The smaller 
arterioles and resistance arteries (the focus of my research) are able to regulate 
peripheral resistance by changing vascular smooth muscle tone to alter the lumen 
size. 
 
 
1.8.1.1 Endothelial function 
 
The  healthy  endothelium  is  an  autocrine  and  paracrine  organ  that  produces 
substances that decrease vascular smooth muscle tone and inhibit inflammation 
and  thrombosis.  These  substances  include  nitric  oxide,  prostacyclin  other 
endothelium dependent vasodilators such as endothelium-derived hyperpolarizing 
factor and plasminogen activators. In disease states or after injury by factors such 
as abnormal strain, temperature or risk factors for atherosclerosis, the endothelium 
produces  substances  that  increase  vascular  tone,  promote  inflammation  and 
enhance  thrombosis.  These  substances  include  cytokines,  growth  factors, 
endothelins and plasminogen inhibitors.   44 
 
The  principle  vasodilators  produced  by  the  endothelium  include  nitric  oxide, 
prostacyclin and endothelium- derived hyperpolarising factor (EDHF).  Of these 
nitric oxide has a central role in mediating many functions of the endothelium 
aside from vasodilation (Alexander and Dzau, 2000), (Kinlay, 2007). 
 
 
1.8.1.2 Nitric oxide  
 
Nitric oxide is generated in the endothelium from the amino acid L-arginine by 
nitric oxide synthase (NOS). Nitric oxide diffuses through the arterial wall and 
enters vascular smooth muscle cells in the media, where it increases the activity of 
guanylate  cyclase  and  the  concentration  of  cyclic  guanosine  monophosphate 
(cGMP). The increased level of cGMP relaxes vascular smooth muscle and leads 
to vasodilation. 
 
1.8.1.3 Prostacyclin 
 
Prostacyclin  is  another  endothelial  product  that  induces  arterial  dilation.  It  is 
produced from arachidonic acid by cyclooxygenase in response to shear stress or 
certain  factors  that  also  increase  nitric  oxide  production.  Prostacyclin  activates 
adenylate  cyclase  to  increase  production  of  cyclic  adenosine  monophosphate 
(cAMP).   45 
  
1.8.1.4 EDHF 
 
A residual vasodilatory response to various stimuli after blocking nitric oxide and 
prostacyclin generation led to the discovery of EDHF. EDHF appears to be more 
important in the small arteries than large conduit arteries. 
 
1.8.2 Systemic Arteries. 
 
Relaxin may be a circulating endogenous agent capable of regulating vascular tone 
(Bani et al, 1998). In keeping with this hypothesis, relaxin has vascular effects.  
Though the focus of existing studies has been on the uteroplacental bed, which is 
not  typical  of  the  systemic  or  pulmonary  circulations,  two  recent  studies  have 
examined the effect of this hormone in other vessels.  Bani et al examined vascular 
smooth muscle cells cultured form bovine aorta. These cells were incubated with 
relaxin at concentrations ranging from 1nmol/L to 1µmol/L. The expression and 
activity of nitric oxide synthase, production of nitric oxide and the intracellular 
levels of cGMP and calcium (Ca
2+) were determined. The cell morphology and 
signal  transduction  mechanisms  of  these  bovine  aortic  smooth  muscle  cells  in 
response to relaxin were also studied. Relaxin was found to increase the expression 
and activity of inducible nitric oxide synthase (iNOS), nitric oxide production and 
intracellular  concentrations  of  cyclic  GMP.  Concurrently,  relaxin  significantly 
decreased cytosolic Ca
2+ concentrations and caused changes in cell shape and the   46 
actin  cytoskeleton  that  were  consistent  with  cell  relaxation  (Bani  et  al,  1998). 
Danielson et al have shown that relaxin causes renal vasodilation and this will be 
discussed further in a later section (Danielson et al, 1999). 
 
Relaxin  has  recently  been  described  as  a  "potential  new  treatment  for 
vasoconstrictive disorders". (Whelan J, 2000).  However, its vasodilatory action 
was first recognised over forty  years ago. Casten et al in an uncontrolled trial, 
found that, in patients with severe obliterative peripheral vascular disease (PVD), 
treated  with  intramuscular  injections  of  porcine  relaxin,  there  was  consistent 
healing of ischaemic ulcerations (Casten et al, 1960). Patients also reported an 
improvement in symptoms of intermittent claudication and rest pain although there 
was a return of symptoms with cessation of the treatment. Interestingly, patients in 
this  trial  who  also  had  coexistent  severe  coronary  artery  disease,  reported  a 
dramatic improvement with regard to their nitroglycerin requirements. One patient 
who, prior to treatment, had required an average of 100 nitroglycerin tablets per 
week, only needed 2-3 tablets during relaxin therapy.  
 
A  phase  II  clinical  trial  of  patients  with  peripheral  arterial  disease  who  have 
recently undergone surgical revascularization of a lower extremity and who have at 
least  one  unhealed  ischaemic  or  operative  wound  in  that  region,  is  currently 
underway. Treatment consists of a subcutaneous infusion of relaxin at 10, 25, or 
100µg kg 
-1 day
-1 or placebo. The study will evaluate the time to complete wound 
healing as well as a range of related parameters. As peripheral arterial disease is   47 
often  accompanied  by  renal  disease,  the  study  will  also  evaluate  the  effect  of 
relaxin on renal function (Whelan, 2000). The results of this study have yet to be 
published. 
 
It has been noted that Raynaud's phenomenon, related to vasoconstriction in the 
arteries in the fingers, disappears during pregnancy (when relaxin levels are at their 
highest).  (Casten,  1958).  This  observation  would  therefore  support  relaxin’s 
vasodilatory effect in humans.  
Also in keeping with its vasodilatory action, relaxin has been found to decrease 
blood pressure and blunt responses to vasoconstrictors of mesenteric vessels in 
spontaneously  hypertensive  rats.  Massicotte  et  al  investigated  the  vascular 
reactivity  to  angiotensin  II,  arginine-vasopressin  and  norepinephrine  in  the 
perfused  mesenteric  artery  and  portal  vein  of  control  and  relaxin-treated  virgin 
spontaneously  hypertensive  rats.  The  latter  received  an  intravenous  infusion  of 
75ng/hr purified rat relaxin for 2 days, whereas the controls were given an equal 
infusion of saline. All of the animals were then killed and their tissues processed 
for in vitro study. In the perfused mesenteric artery, the concentration-response 
curves for arginine-vasopressin and norepinephrine were shifted to the right by a 
factor of about 2 (p<0.05 and p<0.005, respectively) after relaxin treatment. In the 
isolated portal vein, the response to angiotensin II was not affected; the effect of 
norepinephrine  was  slightly  displaced  to  the  right  (increase  in  EC50)  and  the 
maximum  response  remained  unchanged.  Relaxin,  however,  has  no  effect  on 
Wiskar - Kyoto controls. (Massicotte et al, 1989). 
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1.8.3  Renal Arteries. 
 
Relaxin is a potent renal vasodilator. (Danielson et al, 1999).  After several days of 
treatment  with  either  purified  porcine  relaxin  or  recombinant  human  relaxin, 
effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) increased 
by  40%  in  adult  female  rats.  This  was  also  observed  in  ovariectomized  rats, 
suggesting  that  neither  oestrogen  nor  progesterone  is  necessary  for  the  renal 
response to relaxin. Further to this, the role of relaxin on the renal vasculature 
during pregnancy has been investigated. Striking changes are seen in the maternal 
cardiovascular  system  during  pregnancy.  Cardiac  output,  global  arterial 
compliance, effective renal plasma flow (ERPF) and GFR rise from 30% to 80%. 
Vascular  resistance  and  blood  pressure  decrease.  These  alterations  begin 
immediately after conception, peak by the end of the first or the beginning of the 
second  trimester  and  persist  throughout  gestation.  Traditionally,  oestrogen  has 
been viewed as the uterine and systemic vasodilator of pregnancy but this hormone 
has little effect on the renal circulation. (Christy et al, 1974).  
 
Novak et al used two approaches to eliminate relaxin or its biological activity from 
the circulation: ovariectomy and administration of relaxin neutralizing antibodies. 
(To maintain pregnancy in the ovariectomized rats, silastic tubes containing 17β 
oestradiol and progesterone were implanted). Neutralizing mAb against rat relaxin 
(MCA1) or control mAb against fluorescein (MCAF) was administered daily. They 
showed that the relaxin neutralizing antibody administered to pregnant Long-Evans   49 
rats  completely  abolished  the  increase  in  GFR  and  ERPF  associated  with 
pregnancy.    The  same  was  seen  in  the  ovariectomized,  steroid  replaced  rats. 
Therefore,  relaxin  is  in  fact  essential  for  renal  vasodilation  during  pregnancy. 
(Novak et al, 2001).
                 
Evidence of interaction between relaxin and other vasoactive peptides has been 
demonstrated in the renal arteries. Relaxin attenuates the vasoconstrictor effect of 
angiotensin II (Danielson et al, 1999). 
 
 
1.8.4   Relaxin and Myogenic Reactivity. 
 
Myogenic reactivity is defined as the response (either constriction or dilation) of an 
artery  to  a  rapid  change  in  intraluminal  pressure.  Novak  et  al  investigated  the 
myogenic responses of small renal and mesenteric arteries in relaxin-treated Long-
Evans rats. They found that arteries from relaxin-treated rats constrict less than 
those from vehicle-treated rats in response to an increase in intraluminal pressure. 
(Novak et al, 2002). 
 
In a previous study, Novak et al had demonstrated that circulating relaxin mediates 
myogenic reactivity of isolated small renal arteries in gravid rats. When relaxin 
neutralizing antibodies were administered or pregnant rats were ovariectomized, 
myogenic reactivity was restored to virgin levels (Novak et al, 2001). Thus Novak   50 
et al, have demonstrated the influence of relaxin on myogenic reactivity in both the 
pregnant and non- pregnant state. 
 
 
1.8.5 Penile Arteries .  
 
Further evidence of relaxin’s vasodilatory action has been demonstrated. Bigazzi et 
al  showed  that  local  injection  of  relaxin  into  the  cavernous  body  of  human 
volunteers increased blood flow in the deep penile artery. This was evaluated by 
echo Doppler apparatus (Bigazzi et al, 1995).  
 
 
1.8.6 Uteroplacental Arteries.  
 
It should be noted though that relaxin does not have a vasodilatory effect on all 
blood vessels. Peterssen et al, investigated the effect of synthetic human relaxin 
(hRLX-2) on isolated human myometrium and on uteroplacental arteries from term 
pregnant  women.  Relaxin  did  not  dilate  the  arteries  preconstricted  with 
norepinephrine, endothelin or U46619. (Petersen et al, 1991). 
 
This is in contrast with the findings of Longo et al who investigated the effects of 
recombinant human relaxin on rat uterine arteries and myometrial rings. In rats, 
relaxin did cause uterine artery relaxation. This was noted to be greater at mid   51 
pregnancy  compared  to  term.  Relaxin  was  also  found  to  inhibit  spontaneous 
contractions at mid pregnancy but not at term. Relaxin had no effect on oxytocin- 
or  indolactam-V-induced  contractions.  (Indolactam-V  is  a  protein  kinase  C 
activator). (Longo et al, 2003). 
 
1.8.7 Pulmonary Arteries.  
 
During my MD thesis, I have investigated the potential role of relaxin in human 
pulmonary resistance arteries.  Prior to this, the vasoactive role of relaxin in human 
pulmonary  arteries  had  not  been  described.  The  methods  and  results  shall  be 
discussed in detail in later chapters (2 and 3).  
 
 
1.8.8  Veins. 
 
Prior to my work on human long saphenous veins as part of my MD thesis, the 
effect  of  relaxin  on  the  human  venous  system  had  not  been  described.  The 
methodology used will be described in Chapter 2 and the results will be described 
in Chapter 5. 
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1.9  RELAXIN AND THE HEART. 
 
In recent years, evidence is accumulating that relaxin has a major influence on the 
cardiovascular system and may be involved in cardiovascular regulation. (Bigazzi 
et al, 2001). Relaxin has positive chronotropic actions and this may contribute to 
the increase in cardiac output seen in early pregnancy. During the first trimester, 
cardiac output increases by about 40%. During this time relaxin levels are at their 
highest peaking at week 10. 
  
 
1.9.1 The Heart as a Source of Relaxin 
 
The heart has been identified both as an additional source of relaxin and also as a 
target  for  this  hormone  (Taylor  et  al,  1994).    Antibody-directed,  complement-
induced  erythrocyte  lysis  (reverse  haemolytic  plaque  assay)  around  atrial 
cardiocytes was used to determine whether this cell type possesses the capacity to 
secrete  relaxin.  After  two  hours  of  incubaton,  33  +/-  4%  (n=3)  of  cardiocytes 
derived  from  the  atria  of  neonatal  rats  secreted  detectable  amounts  of 
immunoreactive relaxin (i.e. formed plaques) when cultured in monolayers. The 
observation that only one third of atrial cardiocytes secreted relaxin under basal 
conditions is consistent with a similar study which reported that only a subset of 
(27%) of rat atrial cardiocytes secreted atrial natriuretic peptide (ANP) under non-
stimulated conditions.  (Miller and Southerland, 1990).   53 
Increased culture time of cardiocytes failed to increase the fraction of cardiocytes 
that secreted relaxin. However, the cumulative amount of relaxin secreted after 3 
hours of incubation (plaque area) was 31% greater (p<0.05) than the amount of 
hormone  present  after  1  hour  of  incubation,  providing  evidence  for  sustained 
peptide  secretion  by  cultured  cardiocytes.  The  authors  conclude  that  these  data 
suggest that the source of the endogenous ligand for the specific and high-affinity 
relaxin receptors located in the rat atria is the atrial cardiocyte itself, following on 
from the work performed by Osheroff et al  (Osheroff et al, 1992). 
 
1.9.2 Relaxin and Atrial Binding Sites. 
 
Osheroff et al, demonstrated that specific binding sites for relaxin can be found in 
cardiac tissues, particularly the atria. Nine different rat tissues, including the liver, 
spleen, thymus, kidney, adrenal gland, heart, lung, skin and testis were examined 
for the binding of the tracer 
32 P-
 relaxin (phosphorylated relaxin). Of all of these 
tissues,  specific  binding  was  seen  clearly  in  the  heart  atria.  The  ventricles  by 
contrast did not show detectable binding under these experimental conditions. The 
specificity of binding was demonstrated by the binding displacement of 100pM 
32 
P-
  relaxin  by  100nM  unlabelled  relaxin  but  not  by  100nM  insulin  like  growth 
factor I (IGF-I), insulin, angiotensin II and atrial natriuretic peptide (Osheroff et al, 
1992). 
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These specific and high affinity relaxin receptors present in both male and female 
rat atria are regulated differently than the relaxin receptors in the uterus. It was 
found  that  the  relaxin  binding  in  the  uterus  was  diminished  by  53%  overall 
following ovariectomy but was restored to 90% of normal levels when treated with 
oestrogen. Relaxin binding in the heart however was not affected by ovariectomy 
or oestrogen therapy.
    This is in keeping with the findings, previously described, 
demonstrating  the  lack  of  oestrogen  requirement  of  relaxin  for  its  renal 
vasodilatory action. (Danielson et al, 1999). 
 
 
1.9.3 Inotropic and Chronotropic Effects of Relaxin. 
 
The cardiac effects of human gene-2 relaxin (hRlx-2), in isolated rat atria, has been 
investigated (Kakouris et al, 1992). Using hearts from male Sprague-Dawley rats, 
atria were removed and mounted separately under a resting tension of 0.25g in 
20ml organ baths containing Krebs’ bicarbonate buffer. Right atria were allowed to 
beat spontaneously, whereas left atria were driven at 5 Hz with square-wave pulses 
of 2ms at 1.5 times the threshold voltage with a stimulator. Synthetic hRlx-2 (0.03-
3 nmol/l) increased the heart rate of contraction in rat spontaneously beating right 
atria by a maximum of 131 (15) beats per minute from a baseline of 179 (25) beats 
per  minute.  The  EC50,  i.e.  the  concentration  required  to  produce  50%  of  the 
maximal response, was 0.09 (SE 0.03) nmol/l. In the electrically driven left atria, 
synthetic hRlx-2 increased the force of contraction by a maximum of 0.19 (0.03) g   55 
from a baseline of 0.15 (0.02) g (EC50 =0.31 (0.02) nmol/l).  The authors noted that 
the EC50 value of 0.1-0.3 nmol/l for synthetic hRlx-2 in isolated rat atria is lower 
than that of endothelin, angiotension II or isoprenaline, making relaxin one of the 
most potent chronotropic and inotropic agents known.  
 
More recently, Debrah et al, have shown that relaxin increases the cardiac output 
and reduces systemic arterial load in hypertensive rats (Debrah et al, 2005). Two 
models were used in this study: Long-Evans rats chronically administered with 
angiotensin II (AII) and spontaneously hypertensive rats (SHR). Debrah et al had 
noted and as I describe elsewhere, relaxin antagonizes the action of AII in rats. 
(Danielson et al,1999). Cardiac output and systemic arterial load were quantified 
by systemic vascular resistance (SVR) and AC g   (global arterial compliance). Rats 
were either administered relaxin acutely over a 6 hour period or chronically over 6 
days. 
 
In rats with AII-induced hypertension, acute RLX administration (up to 6 hours) 
significantly increased CO and AC g    (24.9+/-3.9 and 34.3+/-12.6% above baseline 
respectively)  and  significantly  decreased  SVR  (17.2+/-3.5%)  without  changing 
mean arterial pressure (MAP). In contrast, acute RLX administration to SHR and 
normotensive rats for up to 6 hours failed to produce any significant change in CO, 
AC g , SVR or MAP. However, chronic administration of RLX (1 to 7 days) to 
SHR yielded significant changes (24.0+/-8.1 and 22.3+/-6.6% increases in CO and 
AC g , respectively, and a 13.3+/-5.3% decrease in SVR with no change in MAP.   56 
Therefore,  the  time  course  to  RLX  treatment  is  dependent  on  the  model  of 
hypertension  as  rats  with  AII-induced  hypertension  responded  more  rapidly  to 
RLX administration than SHR.  
 
Debrah et al have since shown that relaxin is essential for the systemic vasodilation 
and increased global arterial compliance during early pregnancy in conscious rats 
(Debrah  et  al,  2006).  They  administered  relaxin  neutralizing  antibodies  daily 
beginning  on  day  8  of  gestation  to  block  the  functional  effects  of  circulating 
relaxin and used an antibody against fluorescein as a control. In the pregnant rats 
administered the relaxin neutralising antibody, there was no gestational increase in 
stroke volume, cardiac output and global arterial compliance or decrease in SVR, 
that would be expected and which was observed in the pregnant control rats. This 
suggests that relaxin mediates the transition of changes observed in the systemic 
circulation from the non-pregnant to the pregnant state in the rat model. 
 
1.9.4 Relaxin and Heart Failure. 
 
Relaxin production is increased in heart failure, higher levels correlating with the 
severity  of  heart  failure.  (Dschietzig  et  al,  2001).  In  this  study,  patients  were 
classified  as  having  severe  heart  failure  if  in  functional  class New  York  Heart 
Association (NYHA) class IV who required intensive care treatment for acute left 
heart decompensation (orthopnoea and signs of severe pulmonary congestion) with 
a pulmonary wedge pressure (PCWP) of >25mmHg and cardiac index (CI) < 2.5   57 
l/min/m
2 .
 Acute ischaemia was excluded on the basis of electrocardiography as 
well  as  kinetics  of  enzymes  (troponins,  creatinine  kinase)  and  myoglobin.  The 
mean left ventricular ejection fraction (LVEF) was 19%. Patients were assigned to 
the  moderate  congestive  heart  failure  (CHF)  group  if  in  NYHA  class    II  and 
displayed a PCWP <20mmHg and a CI > 2.5 l/min/m
2  . The mean LVEF of these 
patients  was  27%.  The  controls  were  patients  who  underwent  cardiac 
catheterization for suspected coronary artery disease and in whom no structural 
cardiovascular disease was detected. 
 
In all groups, catheters were positioned in the pulmonary artery (PA) (Swan Ganz), 
the coronary sinus (CS), and the left ventricle (LV) under fluoroscopic control. 
Blood sampling and haemodynamic measurements were then carried out. Whilst 
men and women with normal coronary arteries and normal left ventricular systolic 
function were noted to have plasma concentrations in the range 1-2 pg/ml, patients 
with mild to moderate heart failure, had plasma relaxin concentrations 5-10 pg/ml 
and those with severe heart failure concentrations of 15-20 pg/ml. Eleven out of 
the fourteen patients with severe CHF (i.e. 79%) showed higher relaxin plasma 
levels in the coronary sinus than in the left ventricle which indicates net coronary 
release of relaxin in the majority of patients suffering from severe heart failure. 
 
The same group found that myocardial expression of the two relaxin genes, (H1 
and H2) correlates with the severity of heart failure. For the RNA analysis, control 
samples were human total ventricular RNA from healthy individuals and a sample   58 
from one donor heart that was not transplanted.  Failing  myocardium  was from 
patients with dilated cardiomyopathy and ischaemic heart disease who underwent 
partial ventriculectomy or transplantation. 
 
Dschietzig et al demonstrated pronounced up-regulation of GAPDH-normalized 
H1 mRNA (failing hearts, 14.4+/-2.4 vs. non-failing hearts 1.0+/-0.5 arbitary units; 
<0.05) and a moderate increase in H2 mRNA (2.6+/-0.4 vs. 1.0+/-0.2 units, <0.05) 
in left ventricular specimens of failing hearts compared with non-failing hearts. 
Results for right atrial H2 mRNA also showed a more pronounced elevation in 
failing  hearts  (3.8+/-1.0  vs.  1.0+/-0.1  units,  <0.05).  In  contrast,  expression  of 
relaxin mRNA did not appear to differ in mammary arteries and saphenous veins 
from patients with normal heart function and patients with chronic heart failure. 
Increased  ventricular  filling  pressures  results  in  up-regulation  of  relaxin 
expression. Elevation of left ventricular end diastolic pressure from 5 to 25mmHg 
up-regulates preprorelaxin (which processes the precursor of relaxin) mRNA in 
isolated rat hearts. In contrast, elevation of both right and left atrial pressures has 
no effect on the expression of relaxin mRNA. 
 
In severe heart failure, a significant inverse correlation was found between relaxin 
and endothelin-1 (ET-1).  ET-1 represents one of the most powerful mediators in 
CHF progression. Patients in this group (i.e. severe heart failure) with high relaxin 
levels had the lowest  circulating levels of ET-1. It would seem, therefore, that   59 
relaxin may be produced as a compensatory mediator in cardiovascular disease. In 
patients with moderate CHF and in controls, no such correlation was seen. 
 
1.9.5 NT pro BNP and Heart Failure 
 
Another peptide, N-terminal pro B type natriuretic peptide (NT pro BNP) has been 
shown to be elevated in patients with heart failure. As part of my MD thesis, I 
investigated whether the plasma concentration of relaxin predicts clinical outcome 
in patients with CHF and compared with this NT pro BNP (see chapter 6). I will 
therefore at this stage, describe the peptide NT pro BNP in more detail. 
In the early 1980s, DeBold et al observed that extracts of atrial tissue infused into 
rats caused a massive diuresis (DeBold et al, 1981). From this work came the 
isolation of atrial natriuretic peptide (ANP), the first in the family of natriuretic 
peptides (DeBold, 1985).  A decade later, the second member of the family was 
described, B-type natriuretic peptide (BNP).  Since then, four different natriuretic 
peptides have been described: ANP, BNP, C-type natriuretic peptide (CNP) and D-
type natriuretic peptide (DNP).  They all contain a characteristic 17 amino-acid 
ring structure, formed by a disulfide bridge between two cysteine residues.  The 
amino- and carboxy- terminal tail varies between the different peptides: ANP has a 
28 amino acid polypeptide, BNP a 32 amino acid polypeptide, CNP a 53 amino 
acid polypeptide and DNP a 38 amino acid polypeptide.  They all exist as pro-
hormones  with  relatively  high  molecular  weight,  which  are  cleaved  to  active 
moieties before release into the circulation.    60 
BNP is released in bursts as a 108 amino acid prohormone which is then cleaved to 
form biologically active BNP, a 32 amino acid molecule and the 76 amino acid 
molecule, NT-proBNP.  Figure 1.2 summaries this process.   
 
Figure 1.3  Structure and formation of BNP and NT-proBNP (adapted from 
Hall, 2004). 
 
 
 
 
BNP,  and  more  recently  NT-proBNP  have  been  recognised  to  be  of  particular 
importance  in  heart  failure.  The  predominant  source  of  BNP  in  humans  is  the 
ventricular myocardium (Hunt, 1997).  In patients with LV systolic dysfunction   61 
both BNP and NT-proBNP  are elevated, however, increases in  NT-proBNP are 
two-to ten-fold greater than increases in BNP.  The explanation for this is unknown.  
Both  BNP  and  NT-proBNP  can  be  measured  by  radioimmunoassay  (RI).  The 
combination of its longer half-life and greater increases in heart failure, may make 
NT-proBNP a better marker of heart failure (Hunt, 1997).  Recently, NT-proBNP 
has been shown to be elevated in patients with heart failure, post-MI LV systolic 
dysfunction and asymptomatic LV dysfunction (Hobbs et al, 2002), (Masson et al, 
2002), (Hunt et al, 1997), (Richards et al, 1998) , (Groenning et al, 2002). 
 
 
1.9.6 Relaxin and Cardiac Anaphylaxis 
 
Cardiac anaphylaxis refers to the functional and metabolic changes in the heart 
caused  by  the  anaphylactic  release  of  histamine  and  vasoactive  products  of 
arachidonic  acid  cascade  by  mast  cells  and  basophils.  As  in  most  type  1 
hypersensitivity-based diseases, histamine plays a key role in the pathophysiology 
of cardiac anaphylaxis. In the heart, mast cell activation and histamine release are 
controlled  by  multiple  endogenous  mechanisms,  including  adrenergic  neural 
control, histamine-dependent negative feedback operated through H2 receptors and 
the endogenous generation of nitric oxide and carbon monoxide. 
 
A reliable model of cardiac anaphylaxis ex vivo can be reproduced using perfused 
hearts isolated  from sensitized  guinea pigs  and  subjected to challenge  with the   62 
specific  antigen.  A  typical  anaphylactic  crisis  is  characterized  by  arrhythmias, 
sinus tachycardia and increase in the strength of contraction. These mechanical 
abnormalities are accompanied by a fast, short lasting decrease in the coronary 
flow followed by a sustained flow increase. 
 
Masini et al demonstrated that ex vivo perfusion of hearts isolated from ovalbumin-
sensitised  guinea  pigs  with  relaxin  affords  a  marked  protection  against 
anaphylactic reaction induced by challenge with the specific antigen. They found 
that the protective effect of relaxin was exerted at low, nanomolar concentrations 
(30ngml 
-1) and for short exposure times (30 minutes). A significant reduction of 
histamine  release  from  resident  mast  cells  (the  main  repository  of  cardiac 
histamine)  was  seen.  No  significant  changes  were  observed  in  beat  rate  or 
contraction strength. No short-lasting decrease in coronary flow took place and the 
subsequent  flow  increase  was significantly  higher  than  in  the untreated  control 
hearts (Masini et al, 2002). 
 
1.9.7 Relaxin and Prevention of Cardiac Ischaemia/Reperfusion Injury 
 
Relaxin has been shown, as detailed above, to increase coronary blood flow and 
acts as a positive chronotropic and inotropic agent in the heart. Perna et al, tested 
the  therapeutic  potential  of  relaxin  in  a  swine  model  of  ischaemia/reperfusion-
induced acute myocardial infarction which is used to test cardiotropic drugs.  
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Ischaemia for 30 minutes was obtained by transient ligation of the left anterior 
descending artery after the 2
nd diagonal branch and was followed by reperfusion 
for a further 3 hours. Five minutes before reperfusion, lidocaine was administered 
to reduce the occurrence of lethal ventricular fibrillation. Relaxin was infused at 
reperfusion through  the right  atrial  catheter.  Measurements  of  blood  and  tissue 
markers of myocardial injury and inflammation were taken. In addition, functional 
evaluation of  myocardial  salvage  by  cardiac  single-  photon  emission  computed 
tomography (SPECT) was performed. By using the tracer, 
201Thallium chloride 
(which is a potassium competitor and therefore labels viable cardiac cells), the 
investigators  were  able  to  distinguish  between  normal  myocardium,  ischaemic 
myocardium and irreversibly damaged myocardium. 
 
Administration  of  relaxin  caused  a  statistically  significant  reduction  of  serum 
myoglobin, CK-MB and troponin T (markers of myocardial cell damage) which 
rose markedly in the control animals given the vehicle alone. Relaxin also reduced 
myeloperoxidase  (MPO),  a  marker  of  inflammatory  leukocyte  infiltration  and 
malondialdehyde  (MDA),  a  marker  of  free  radical-mediated  cell  damage.  By 
SPECT analysis, in the relaxin treated swine, there was a striking reduction of the 
irreversibly  injured  myocardial  tissue  (Student’s  t-test:  p<0.05).  The  relaxin-
induced  salvage  improved  contractile  performance  of  the  heart,  indicated  by  a 
stable increase in cardiac index. The authors point out that the protection afforded 
by relaxin is exerted at plasma levels which are within the physiological range in 
humans. They feel that clinical trials with relaxin as adjunctive therapy to catheter-  64 
based coronary angioplasty in patients with acute myocardial infarction may be 
warranted (Perna et al, 2005). 
 
 
1.10 RELAXIN AND FLUID BALANCE. 
 
During pregnancy, there is a decrease in plasma osmolality which begins early 
around gestational week 5 in women which returns to normal by 2 weeks post 
partum. This has also been demonstrated in the rat where the decrease in plasma 
osmolality is thought to be due to a decrease  in both the threshold for thirst and for 
arginine vasopressin (AVP) release such that the relationship P osmol  /PAVP shifts to 
the left. Thus a decrease of about 10 mosmol/kg occurs because more water is 
drunk and less excreted because the PAVP  is seemingly inappropriately high for the  
P  osmol  . The decrease in P  osmol     is dependent on the presence of the ovary and 
treatment of rats with various amounts of oestrogen and/or progesterone does have 
a small effect on the P osmol  /PAVP   relationship. However, treatment of rats or non-
pregnant women with the appropriate amount of ovarian steroids does not produce 
the changes in the P osmol  /PAVP   relationship seen in pregnancy. (Barron et al, 1986; 
Lindheimer et al, 1989). Weisinger et al, noted that relaxin concentration increases 
in the rat and in the pregnant women at the appropriate stage of pregnancy and 
investigated  this  further.  They  found  that  in  ovariectomized  rats  treated  with 
intravenous synthetic human relaxin, P osmol  was significantly lower (p<0.001) than 
that in the two control groups (either no treatment or treatment with vehicle), but   65 
the  PAVP    was  unchanged.  This  decrease  in  osmotic  threshold  for  AVP  release 
produced  by  intravenous  relaxin  in  ovariectomized  rats,  which  is  observed  in 
pregnant  women  and  rats,  was  achieved  at  concentrations  of  relaxin  found  in 
pregnant rats. Weisinger et al were unable to demonstrate the exact mechanism of 
action.  
 
Robertson  et  al,  showed  that  relaxin  stimulates  vasopressin  secretion  from  the 
posterior pituitary gland, triggering thirst and increasing water intake. (Robertson 
et al, 1991).   
This key role in fluid balance played by relaxin during pregnancy has been further 
demonstrated by Novak et al.  Neutralizing antibodies against rat relaxin (MCA1) 
or control antibodies against fluoroscein (MCAF) were administered to pregnant 
Long-Evans rats. In pregnancy there is an expected rise in effective renal plasma 
flow (ERPF) and glomerular filtration rate (GFR) of between 30 and 80%. This did 
not  occur  in  the  rats  that  received  the  neutralizing  MCA1  (ie  the  relaxin 
neutralizing  antibody).  The  usual  decreases  in  plasma  osmolality  and  sodium 
concentration found during pregnancy were also inhibited by the MCA1 antibody. 
Relaxin therefore plays a central role in fluid homeostasis (Novak et al, 2001) 
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1.11 RELAXIN AND VASCULAR ENDOTHELIAL GROWTH FACTOR. 
 
The actions of relaxin in pregnancy have been well documented. By inhibiting 
collagen synthesis and promoting collagen breakdown through increased synthesis 
of collagenase, relaxin facilitates enlargement of the uterus, abdomen and breasts 
and loosens the pelvic ligaments. It is also thought to mediate blood vessel dilation, 
both in pregnancy and during the menstrual cycle. (Unemori et al, 1999).  
 
The  importance  of  relaxin  in  early  pregnancy  centres  on  the  induction  of 
expression  of  an  angiogenic  agent, vascular endothelial  growth  factor  (VEGF).  
This suggests that relaxin may be involved in the preparation of the endometrium 
for nidation. The evidence for the induction of VEGF by  relaxin expression is 
supported  clinically.  In  a  recent  trial  investigating  relaxin  as  a  potential  anti-
fibrotic agent for the treatment of systemic sclerosis, (Seibold et al, 2000), the 
most  commonly  reported  side  effect  of  treatment,  was  menorrhagia.  This  in 
keeping  with  the  hypothesis  that  relaxin  mediates  neovascularization  of  the 
endothelial lining. 
 
Furthermore, relaxin is also responsible for stimulating ischaemic wound healing 
by increasing blood flow through vasodilation and angiogenesis. Rats were infused 
subcutaneously with recombinant human relaxin.  Fluid and cells collected from 
the wounds were analysed for VEGF and basic fibroblast growth factor (bFGF);   67 
another angiogenic agent. Expression of both factors was increased at wound sites 
in relaxin-treated rats compared with control rats (Arnold et al, 2000). 
 
Another action of relaxin may also be responsible for the increase in menstrual 
blood  flow  mentioned  above.  In  a  study  of  platelet  function,  preincubation  of 
human  platelets  with  relaxin  resulted  in  a  significant,  concentration  dependent, 
inhibition  of  platelet  aggregation.  This  was  accompanied  by  an  elevation  of 
intraplatelet cGMP and a decrease in the rise of cytosolic calcium levels. Its effects 
appeared  to  be  mediated  through  nitric  oxide. This  antiaggregatory  property  of 
relaxin suggests that it may play a role as an antithrombotic agent. (Bani et al, 
1995). 
 
Hypertension  affects  10-15%  of  the  adult  population  leading  to  structural 
remodeling of the left ventricular myocardium and eventually heart failure. Cardiac 
fibrosis is a hallmark of hypertensive heart disease and interferes with with normal 
structure  and  function  of  myocardium.  Cardiac  fibroblasts  are  activated  and 
differentiate  into  myofibroblasts  after  cardiomyocyte  death,  inflammation 
enhanced workload, hypertrophy and stimulation by a number of hormones (e.g. 
angiotensin II), cytokines (e.g. interleukin-1) and growth factors (e.g. transforming 
factor- β [TGF-β]. 
 
Renal fibrosis is another major complication associated with the development and 
progression of hypertension. Collagens accumulate around renal resistance vessels,   68 
glomeruli  and  interstitium  which  contributes  to  remodeling  and  progression  of 
renal  injury.  Relaxin  has  been  shown  to  reduce  collagen  synthesis,  increase 
expression  of  matrix  metalloproteinases  (MMPs)  to  degrade  collagen  and 
antagonize the influence of pro-fibrotic factors. 
 
Lekgabe et al, investigated the antifibrotic effects of relaxin on cardiac and renal 
fibrosis.  (Lekgabe  et  al,  2005).  They  studied  spontaneously  hypertensive  rats 
(SHR) and normotensive Wistar-Kyoto rats (WKY). They found that over a 14 day 
period, H2 relaxin significantly reduced the elevated collagen content in the left 
ventricle and kidney, in particular types I, II and V collagen. In addition to this, H2 
relaxin  inhibited  fibroblast  proliferation  and  differentiation  and  induced  a 
significant  rise  in  MMP-2  expression.  The  authors  conclude  that  since  relaxin 
reverses  cardiac  and  renal  fibrosis  that  it  may  have  therapeutic  potential  in 
hypertensive disease. 
 
 
1.12  SUMMARY  OF  THE  ACTIONS  OF  THE  RELAXIN  FAMILY 
PEPTIDES. 
 
Knowledge of the relaxin family peptides and their receptors with their actions is 
developing at a rapid pace. Figure 1.4 below summarises what is currently known 
of the tissue localisation of the relaxin family peptides, their receptors and their 
functions.  Adapted from van der Westhuizen et al, 2008.   69 
 
Figure 1.4  Relaxin family peptides, their receptors and their functions. 
 
van der Westhuizen et al, 2008   70 
1.13 THE MECHANISM OF ACTION OF RELAXIN. 
 
Although there has been a great deal of work demonstrating the mechanism of 
action of relaxin in animals, little is known of its mechanism of action in humans. 
 
1.13.1 Relaxin and Nitric Oxide. 
 
The  mechanism  of  action  of  relaxin  appears  to  involve  the  stimulation  of  the 
biosynthesis of nitric oxide (NO), a gaseous free radical and potent endogenous 
vasodilator.  Under  physiological  conditions,  the  vasodilatory  action  of  NO  is 
thought  to  be  primarily  an  endothelium-dependent  process.  Endothelial  cells 
constitutively express a Ca 
2+ / calmodulin-dependent isoform of NOS (NOS III or 
eNOS) that continuously produces small amounts of NO, involved in a moment-to-
moment  regulation  of  the  vascular  tone.  Endothelial  cells  also  express  the 
inducible, high- yield NO synthase isoform (NOS II or iNOS), which synthesizes 
greater amounts of NO than NOS III and can be up-regulated by different stimuli, 
especially inflammatory cytokines and mediators. 
Relaxin  generates  nitric  oxide  in  experimental  animals.  Bani  et  al  examined 
vascular smooth muscle cells (VSMCs) cultured from bovine aorta. VSMCs were 
incubated with relaxin at concentrations ranging from 1nmol/l to 1 µmol/l. The 
choice of VSMCs of bovine origin was motivated by the fact that these cells retain 
a distinct muscular phenotype in in vitro culture, including the ability to produce 
nitric oxide (Mollace et al, 1991). Porcine relaxin has been found to be active in   71 
cattle heifers in vivo (Musah et al, 1986). NOS activity was determined in cell 
homogenates by measuring the conversion of [
3H]L-arginine to [
3H]L-citrulline. 
Nitric oxide production was determined by measuring the accumulation of nitrite, 
the  stable  end  product  of  nitric  oxide,  in  bovine  aortic  smooth  muscle  cell 
(BASMC) supernatants. Relaxin was found to increase the expression and activity 
of inducible nitric oxide synthase (iNOS), nitric oxide production and intracellular 
concentrations of cyclic GMP. The addition of the NOS inhibitor L-NMMA (Nω-
monomethyl-L-arginine) abolished the effect of relaxin. This shows that relaxin 
directly activates the L-arginine-NO pathway in bovine arterial SMCs in culture. 
Relaxin was also noted to induce changes in cell shape and the actin cytoskeleton 
that are consistent with cell relaxation. (Bani et al, 1998).   
 
Relaxin  has  also  been  shown  to  upregulate  inducible  nitric  oxide  synthase 
expression and nitric oxide generation in vitro in rat coronary endothelial (RCE) 
cells  (Failli  et  al,  2001).  RCE  cells  were  isolated  from  Wistar  rat  hearts  and 
incubated  in  the  presence  or  absence  of  relaxin  (60ng/ml)  Evaluation  of  nitric 
oxide production was performed by measuring the accumulation of nitrite, a stable 
end product of nitric oxide, in the supernatant of the RCE cells.  Expression of NO 
synthase  isoenzymes  II  and  III  was  analyzed  by  immunocytochemistry.  The 
immunostained RCE cell cultures were examined. The control cells were almost 
negative for NOS II but showed a clear-cut cytoplasmic immunoreactivity for NOS 
III.  A  24  hour  incubation  with  relaxin  caused  a  marked  increase  in  the 
immunoreactivity for NOS II, whereas the immunoreactivity for NOS III was not   72 
affected substantially. Since relaxin does not seem to influence NOS III isoform in 
RCE  cells,  the  authors  suggest  that  NOS  II  contributes  the  major  amounts  of 
biologically  active  NO  in  response  to  relaxin.  The  relaxin  induced  increase  in 
coronary flow in experimental animals is also felt to be nitric oxide dependent  
(Bani  Sacchi,  1995).  More  recently,  Bani’s  group  demonstrated  that  relaxin 
potentiates the expression of iNOS (or NOS II) by endothelial cells from human 
umbilical  vein  in in  vitro  culture (Quattrone  et al,  2004).  Relaxin  treated  cells 
showed an increased expression of NOS II, attaining a maximum with 1000ng/ml 
relaxin, which gave rise to increased NO generation, as shown by nitrite assay. 
This effect of relaxin appears to be mediated by activation of NOS II transcription 
factor NF-kappaB, since it was abolished by the NF-kappaB inhibitors curcumin-
95 and dexamethasone. At variance with NOS II, the constitutive NOS III isoform 
appears unchanged upon relaxin treatment. Relaxin can therefore influence human 
umbilical  vein  endothelial  cells  (HUVEC)  by  up-regulating  the  expression  of 
inducible NOS II mRNA and protein and in this respect, HUVEC behave similarly 
to bovine vascular smooth muscle cells and rat coronary endothelial cells. 
 
Danielson et al found that the relaxin induced renal vasodilatation in both male and 
female Long Evans rats was likely to be nitric oxide dependent. Their study has 
been described previously in section 1.5.2 on renal arteries (Danielson et al, 1999). 
The renal vasodilation and hyperfiltration in the relaxin-treated rats observed on 
day 5 of the infusion was completely abolished by the infusion of Nω-nitro-L-  73 
arginine methyl ester (L-NAME), a substrate competitive inhibitor of NO synthase, 
which was administered intravenously by infusion pump. 
 
Novak et al, investigated the effect of relaxin, on the myogenic reactivity in rat 
renal  arteries  (section  1.5.3),  and  also  tried  to  gain  mechanistic  insight.  Thus 
myogenic  reactivity  was  investigated  following  pretreatment  of  the  small  renal 
vessels  with  the  NO  synthesis  inhibitor  N
G-nitro-L-arginine  methyl  ester  (L-
NAME)  at  0.25mmol/l  for  15  minutes.  Relaxin  treatment  decreased  myogenic 
reactivity  but  in  the  presence  of  L-NAME,  the  myogenic  reactivity  of  relaxin-
treated rat arteries was significantly increased (to the same response as vehicle-
treated rats). 
 
1.13.2 Relaxin and ANP 
 
Relaxin has been reported to increase atrial natriuretic peptide (ANP) secretion, a 
peptide hormone involved in the regulation of blood pressure and fluid balance. 
ANP  is  synthesized  and  secreted  predominantly  by  the  atria  of  the  adult 
mammalian  heart.  Toth  et  al,  investigated  the  effect  of  relaxin  on  the  isolated 
perfused  spontaneously  beating  rat  heart.  A  cyclic  adenosine  monophosphate 
(cAMP)  dependent  protein  kinase  inhibitor  (H-89)  was  found  to  substantially 
reduce the ANP secretory effect of relaxin and a calcium/calmodulin dependent 
protein kinase inhibitor (KN-62) was found to decrease the positive chronotropic 
effect  of  relaxin.  Both  of  these  observations  were  statistically  significant   74 
(p<0.001). The ANP secretory and chronotropic effects of relaxin were thought to 
involve activation of protein kinase C since administration of the protein kinase C 
inhibitor staurosporine at a concentration of 30nM completely blocked the effect of 
relaxin (10nM) on immunoreactive ANP (IR-ANP) secretion (p<0.001) and heart 
rate  (p<0.001).  The  ANP  secretory  and  chronotropic  effects  of  relaxin  in  rats 
appear to be mediated by intracellular signal transduction pathways. (Toth et al, 
1996).  
 
 
1.13.3 Relaxin and NO-cGMP and cAMP Pathways. 
 
Nitric  oxide  is  generated  in  the  vascular  endothelium  from  L-arginine  by  a 
calcium-dependent  NO  synthase.  Nitric  oxide  activates  the  soluble  guanylate 
cyclase  of  the  vascular  smooth  muscle,  which  increases  intracellular  cyclic 
guanosine  monophosphate  (cGMP)  concentration,  thus  causing  smooth  muscle 
relaxation. 
 
The vasodilatory effect of relaxin on the pregnant rat uterine artery has previously 
been described (section 1.5.5). Longo et al, investigated the mechanism of action 
of  relaxin  by  using  three  inhibitors  to  examine  the  second-messenger  systems 
involved. Therefore, relaxin effects in segments of uterine arteries were studied 
after preincubation for 30 minutes with, the NO synthetase inhibitor, Nω-nitro-L-
arginine  methyl  ester  (L-NAME  10
-4  mol/l),  the  soluble  guanylate  cyclase   75 
inhibitor,  1H-oxadiazolo-qui-noxaline-1-one (ODQ,  10
-5  mol/l)  or the  adenylate 
cyclase  inhibitor,  9-tetrahydro-2-furanyl-9-H-purin-6-amine  (SQ-22,536,10
-5 
mol/l).  L-NAME,  ODQ  and  SQ-22,536  all  decreased  responses  to  relaxin  in 
uterine artery rings in mid-pregnant rats. Blockade of the NO synthase with L-
NAME or of soluble guanylate cyclase with ODQ caused a significant inhibition of 
the relaxant effect of relaxin. This suggests that the NO-cGMP pathway is one of 
the  second  messenger  systems  that  mediates  the  vascular  effects  of  relaxin  in 
pregnancy in rats. Inhibition of the adenylate cyclase, the enzyme responsible for 
the production of cAMP, with SQ-22,536 decreased the response of the uterine 
arteries to relaxin, suggesting that cAMP is also involved in the vascular effects of 
relaxin in pregnancy (Longo et al, 2003). 
 
The  molecular  mechanism  of  the  anti-anaphylactic  action  of  relaxin  previously 
discussed  (section  1.6.5)  appeared  to  involve  an  up-regulation  of  the  NO 
biosynthetic pathway. Upon perfusion with relaxin, the release of nitrite (the stable 
end product of NO metabolism) increased in the perfusates. In addition, relaxin 
treatment caused an increase in the expression of iNOS protein and in the activity 
of NOS. Tissue levels of cGMP were also increased by treatment with relaxin. 
(Masini et al, 2002). 
 
It should be noted that the work described in section 1.9, above, has focused on the 
mechanism of action of relaxin in animals. As part of my MD thesis, I investigated 
the mechanism of action of relaxin in humans.   76 
 
Aims and Hypothesis 
 
The aim is to characterise the actions and potency of relaxin in human arteries and 
veins, of various calibre, ex vivo  using concentrations similar to those found in the 
plasma  in  physiological  (non-pregnant,  pregnancy)  and  pathophysiological 
(chronic heart failure) states.  I will study the mechanism of action of relaxin. In 
addition, I will study the heart’s possible secretion and extraction of relaxin and 
determine  whether  relaxin  is  of  prognostic  importance  in  heart  failure.  The 
hypothesis is that relaxin is a circulating hormone that has measurable vascular 
effects at biological concentrations and that these actions are of potential benefit in 
cardiovascular disease. 
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CHAPTER 2: 
METHODS. 
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SUMMARY 
 
My thesis was funded by a British Heart Foundation project grant (Project number 
2001/147). In this chapter there will be a detailed description of the methods used 
for each of the studies that comprise the M.D. thesis.  
 
ETHICS 
 
Ethics approval was obtained for all the studies performed in this thesis from the 
West Ethics Committee of the North Glasgow Hospitals University NHS Trust. 
Written informed consent was obtained from all the subjects. 
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2.1  METHODS  FOR  STUDY  OF  EFFECT  OF  RELAXIN  ON  SMALL 
HUMAN  RESISTANCE  ARTERIES  FROM  THE  SYSTEMIC  AND 
PULMONARY CIRCULATIONS. 
 
2.1.1 PATIENTS 
 
The University of Glasgow is located adjacent to the Western Infirmary, Glasgow 
which is a large tertiary referral healthcare centre. Patients attending the cardiology 
and cardiothoracic departments of the Western Infirmary were asked to participate 
in the study.  
Gluteal biopsies taken from patients with coronary heart disease but normal left 
ventricular  systolic  function  provided  the  source  of  the  small  resistance  arteries 
(SRA) from the systemic circulation. All patients with renal failure (creatinine>200 
µmol/l) and diabetes mellitus were excluded from the study. 
Lung tissue obtained from patients undergoing pneumonectomy for cancer provided 
the source of the small resistance arteries from the pulmonary circulation. 
The technique of gluteal biopsy has been used for many  years by our research 
group as a source of SRA. (Hillier et al, 1999; Coats et al, 2001; Petrie et al, 2001).  
Patients attended the Clinical Investigations Research Unit of the Department of 
Medicine  and  Therapeutics.  Transport  was  provided.  Clinical  details  such  as 
smoking history, past medical history of myocardial infarction or hypertension and 
current medication were noted.  
   80 
 
 
2.1.2 MATERIALS 
 
Relaxin was gifted by Connetics Corporation, Palo Alto, USA.  Many thanks to Dr 
Elaine Unemori for this gift. 
 
 
Experiments  were  carried  out  in  physiological  salt  solution  (PSS)  with  the 
following composition (mM): NaCI 118.4, KCI 4.7, MgSO4H2O 1.2, KH2PO4 1.2. 
Na HCO3 24.9, CaCI2 2.5, glucose 11.1, EDTA 0.023 which gives a pH of 7.4 when 
gassed with a 5% CO2 / 95% O2 mixture.   
A  Mulvany-Halpern  four-channel  wire  myograph  (Danish  Myotech,  Aarhus, 
Denmark) was used.  
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2.1.3   SYSTEMIC RESISTANCE ARTERY STUDIES 
 
2.1.3.1 Gluteal Biopsy Procedure and Artery Preparation 
 
Small  resistance  arteries  (SRA)  are  those  blood  vessels  which  contribute  the 
greatest resistance to blood flow, and are therefore most involved in regulating 
blood flow and capillary pressure (Mulvany and Aalkjaer, 1990). These arteries 
can be readily obtained from gluteal biopsies in humans. Resistance arteries are 
those blood vessels which contribute the greatest resistance to blood flow, and are 
therefore most involved in regulating blood flow and capillary pressure (Mulvany 
and Aalkjaer 1990). SRA wire myography is an in vitro technique which allows 
resistance arteries with a diameter of 100 – 500µm to be studied under precise and 
standardised conditions. Use of this technique yields information on the contractile 
or relaxant properties, and morphology, of SRA under isometric tension (Mulvany 
and  Aalkjaer  1990;  Mulvany  and  Halpern  1977).  In  the  present  investigation, 
functional  studies  were  undertaken  with  SRA  because  of  the  physiological 
importance  of  these  blood  vessels.  Wire  myography  was  employed  for  these 
studies  because  this is an  established  technique  in  our  laboratory  (Hillier  et  al 
1999, 2001a; Padmanabhan et al 1999; Petrie et al 2001), in which several arteries 
may be studied at any one time, using one or more protocols. 
The gluteal biopsy was performed by myself under local anaesthetic. 10mls of 1% 
lidocaine was injected into the upper, outer quadrant of the buttock using an aseptic 
technique. Usually the right buttock was used. However if a patient had had a   82 
gluteal biopsy performed previously by  another research fellow for their study, 
then the left buttock was used instead. An incision was made with a scalpel and a 
gluteal biopsy (around the size of a 10 pence coin) was taken. Three to four non-
absorbable sutures were then used to close the skin and a dressing was placed on 
the skin over the sutures. Patients were asked to return to the research unit one 
week later to have the sutures removed by the research nurse. Again, transport was 
provided for this. There were no complications from this procedure. 
The  biopsy  was  placed  in  a  universal  container  in  cold  0.9%  sodium  chloride 
solution and sent by taxi to Caledonian University for dissection of the resistance 
arteries found within the gluteal biopsy. This was performed by Fiona Johnston, 
Research Technician under the guidance of Dr Chris Hillier. Isolating SRA within 
the biopsy requires careful dissection using surgical grade instruments with the aid 
of a high power microscope. The biopsy was placed in a Petri dish filled with ice 
cold  Krebs  buffer,  which  was  regularly  changed  during  the  dissection  process. 
Dissection of the SRA can take several hours. 
Once dissection of the biopsy was complete, the SRA were placed in a universal 
container  and  stored  at  4
oC  in  a  refrigerator  overnight.  Storage  of  resistance 
arteries in this way has been previously demonstrated to have no effect on the 
vasoactive properties of these blood vessels (McIntyre et al, 1998).  
 A single biopsy may yield several blood vessels (average 2 – 4).  Isolated SRA 
were  divided  into  segments  approximately  2mm  long.  When  possible,  four 
resistance arteries, were carefully mounted on two 40-µm-diameter stainless steel 
wires and mounted in the bath of a 4-channel myograph (Halpern & Mulvany,   83 
Danish Myotech, Aarhus, Denmark), in which the wires are attached to a force 
transducer  and micrometer, respectively.  The bath contained physiological salt 
solution (PSS), which gives a pH of 7.4 when gassed with a 5% CO2/95% O2 
mixture and pre-heated at 37°C. These conditions were maintained for the duration 
of  the  experiment.    In  addition,  the  physiological  salt  solution  was  regularly 
changed throughout the experiment.
 
 
2.1.3.2 Experimental Protocol (with intact endothelium) 
 
 
After a rest period of 30 minutes, a normalisation procedure was followed for each 
artery to determine the normalised internal diameter (ID), L0, at which contraction 
is thought to be optimal, and the vessel was set to that diameter (Mulvany and 
Halpern 1977). In the present study, arteries with a normalised ID of 200 – 400µm 
were used. After a rest period of 30 minute each artery was stretched at 1 minute 
intervals to determine the passive exponential wall tension-internal circumference 
(L)  relationship.    From  the  Laplace  equation,  where  P=T/r  (P  is  the  effective 
pressure,  T  is  the  wall  tension  and  r  is  the  internal  radius),  the  equivalent 
circumference (L100) for a transmural pressure of 100mmHg, was calculated for 
each  artery  by  an  iterative  computer  method.  Each  artery  was  then  set  to  the 
normalised internal diameter, L1=0.9 ×L100/π, at which contraction is thought to be 
optimal (Mulvany and Aalkjaer 1990; Mulvany and Halpern 1977).  
Following normalisation, the vessels were left for a further hour. They were then 
exposed to a high (123mM) concentration of potassium (KPSS, solution identical   84 
to PSS except that sodium is replaced by potassium on an equimolar basis) for a 
series of 5 minute periods until repeatable maximal contractions were achieved, 
and then once to 10 µmol/L of norepinephrine (NE). After a plateau contraction 
had  been  attained  with  NE,  3  µmol/L  of  acetylcholine  (ACh)  was  added  to 
stimulate  endothelium-dependent  vasodilatation.  Arteries  that  were  unable  to 
contract to either KPSS or norepinephrine or showed no relaxation to acetylcholine 
(and were therefore considered to have no functionally intact endothelium) were 
discarded.  The  arteries  were  then  incubated  for  a  further  30  minutes  in  Krebs 
solution prior to the commencement of the concentration-response curves (CRC) 
incorporated in the study protocol.  
 
2.1.3.3 Comparative Potency of Relaxin Compared To Other Vasodilators. 
 
Cumulative  concentration  response  curves  (CCRC)  were  then  constructed  in 
vessels pre-constricted with 10
-5M norepinephrine, using substance P (a powerful 
vasodilator, 10
-14M to 10
-9M), epoprostenol (a moderately potent vasodilator, 10
-
11M to 10
-8M), atrial natriuretic peptide (ANP, a weak vasodilator, 10
-11M to 10
-
8M),  and relaxin (concentration range 10
-13 -10
-7M).  
Our research group has studied each of these comparators previously. (Hillier et al, 
1999), (Petrie et al, 2000). 
The concentration of relaxin used will cover the known physiological (pregnant, 
10
-9M  and  non-pregnant  state,  10
-12M) and pathophysiological  (seen  in  chronic 
heart failure, 10
-11M) range of plasma concentrations.   85 
 
 
2.1.3.4 Procedure for Removal of Endothelium and Experimental Protocol in 
De-endothelialised Vessels. 
 
We  were  keen  to  establish  if  the  action  of  relaxin  in  SRA  was  endothelium 
dependent.  Thus,  endothelium  was  mechanically  removed  from  a  further  set  of 
vessels by gently rubbing the luminal side of the arterial wall with a human hair 
(stored  in  ethanol  and  rinsed  with  PSS  before  use).  Endothelial  removal  was 
confirmed by the lack of relaxation to ACh.  A CCRC was then constructed with 
relaxin 10
-13 to 10-
7M.    
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2.1.4 PULMONARY RESISTANCE  ARTERY STUDIES. 
 
2.1.4.1 Artery Preparation. 
 
Lung  tissue  was  placed  in  cold  Krebs-buffer  solution.    Pulmonary  resistance 
arteries  (diameter  <  300  µm,  length  approximately  2mm)  were  dissected  and 
mounted in the myograph as described above and previously (Stirrat et al, 2001). 
 
2.1.4.2 Experimental protocol. 
 
Tension was applied to vessels to give transmural pressures equivalent to 12 – 
16mmHg to simulate in vivo pressures.  Vessels were allowed to equilibrate and 
endothelial integrity was tested, as described above. CCRC were then constructed   
with relaxin 10 
-15 to 10 
-7  M, after preconstricting each vessel with  U46619 – a 
thromboxane A2 mimetic (norepinephrine does not induce sustained constriction 
of human pulmonary vessels).   
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2.1.5 ANALYSIS OF DATA 
 
Responses  (mean  +  standard  error  of  the  mean  [SEM])  are  expressed  as  % 
relaxation from maximally preconstricted levels.   
 
 
2.1.5.1 Comparisons Between Relaxin and Other Vasodilators 
 
Statistical  comparison  of  maximum  responses  (within  the  concentration  range 
tested) was performed using unpaired Student’s t test and Dunnett’s post hoc test 
for  multiple  comparisons.  Comparison  of  curves  was  by  one  way  ANOVA  for 
repeated measures (Hillier et al, 2001b, Jarajapu et al, 2001, Stirrat et al, 2001).  
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2.2 METHODS FOR THE STUDY OF THE MECHANISM OF ACTION OF 
RELAXIN IN SYSTEMIC RESISTANCE ARTERIES. 
 
 
2.2.1 PATIENTS 
 
Patients with coronary heart disease but normal left ventricular systolic function 
were studied.  All patients with renal failure (creatinine>200 µmol/l) and diabetes 
mellitus were excluded from the study. 
Patient  characteristics  such  as  smoking  history  and  current  medication  were 
documented. 
 
 
2.2.2 MATERIALS 
 
Relaxin was gifted by Connetics Corporation, Palo Alto, USA.   
 
Experiments  were  carried  out  in  physiological  salt  solution  (PSS)  with  the 
following composition (mM): NaCI 118.4, KCI 4.7, MgSO4II2O 1.2, KH2PO4 1.2. 
Na HCO3 24.9, CaCI2 2.5, glucose 11.1, EDTA 0.023 which gives a pH of 7.4 when 
gassed with a 5% CO2 / 95% O2 mixture.   
A  Mulvany-Halpern  four-channel  wire  myograph  (Danish  Myotech,  Aarhus, 
Denmark) was used.   89 
2.2.3 GLUTEAL BIOPSY PROCEDURE AND ARTERY PREPARATION 
 
Gluteal  biopsies  were  obtained  under  local  anaesthesia  (1%  lidocaine),  as 
previously described. Resistance arteries (diameter < 300 µm, length approximately 
2mm), were dissected and mounted in the myograph. A Mulvany-Halpern four-
channel wire myograph (Danish Myotech, Aarhus, Denmark) was used. The bath 
was gassed and heated for the duration of the experiment. 
 
 
2.2.4  EXPERIMENTAL PROTOCOL (WITH INTACT ENDOTHELIUM) 
 
Experiments  were  carried  out  in  physiological  salt  solution  (PSS)  with  the 
following composition (mM): NaCI 118.4, KCI 4.7, MgSO4II2O 1.2, KH2PO4 1.2. 
Na HCO3 24.9, CaCI2 2.5, glucose 11.1, EDTA 0.023 which gives a pH of 7.4 when 
gassed with a 5% CO2 / 95% O2 mixture.   
After 30 minutes rest, each artery was set to the normalised internal diameter at 
which contraction is thought to be optimal. The vessels were left for a further hour 
and then repeatedly exposed to a high potassium salt solution until reproducible 
maximal  contractions  were  achieved.    Vessels  were  preconstricted  with  10
-5 
norepinephrine  and  10
-6  ACh  was  added  to  test  for  endothelial  integrity  since 
relaxin  is  endothelium  dependent.  (We  have  demonstrated  this  with  a  previous 
experiment detailed above, section 2.1.3.3).    90 
Cumulative  concentration  response  curves  (CCRC)  were  constructed  in  vessels 
pre-constricted with 10
-5M norepinephrine and relaxin (concentration range 10
-13 -
10
-7M).  
 
2.2.4.1 Relaxin and the Prostacyclin Pathway  
 
CCRCs to relaxin (as above) were constructed to identify the importance of 
prostacyclin – before the following incubation with the cyclooxygenase inhibitor 
indomethacin.(10 
-5 M).  
 
2.2.4.2 Relaxin and EDHF 
 
Next, we studied endothelium-derived hyperpolarising factor – before and 
following incubation with apamin and charybdotoxin, (blockers of Ca 
2+ activated 
K
+ channels).  
 
2.2.4.3 Interaction of Relaxin with Nitric Oxide. 
 
The  bulk  of  the  data  from  studies  in  experimental  animals  suggest  that  relaxin 
exerts at least some of its vasodilator effect via nitric oxide. (Bani, 1997), (Bani et 
al, 1998), (Masini et al, 1997).  We therefore studied the vasorelaxant  effect of 
relaxin in small human  resistance  arteries in the absence and presence  of nitric   91 
oxide synthase (NOS) inhibitors, L- NAME (Nω-nitro-L-arginine methyl ester) and 
L-NOARG (Nω-nitro-L-arginine).  
 
2.2.4.4 Second Messengers Mediating Vasodilator Action of Relaxin. 
 
It  has  been  suggested  that  the  vasodilator action  of relaxin  is  mediated  via the 
second  messengers  cyclic  GMP  and  cyclic  AMP  (Bani,  1997).  We  studied  the 
vasodilator  action  of  relaxin  in  the  presence  of  milrinone  (a  cAMP 
phosphodiesterase inhibitor), zaprinast (a cGMP phosphodiesterase inhibitor) and 
ODQ, a soluble guanylate cyclase inhibitor. 
 
2.2.4.5  Relaxin  and  Patients  taking  Angiotensin  Converting  Enzyme  (ACE) 
Inhibitors. 
 
On gaining mechanistic insight, an unexpected finding was that prior treatment with 
an  ACE  inhibitor  substantially  attenuated  the  vasodilator  effect  of  relaxin. 
Consequently,  all subsequent analyses  were  carried  out  separately,  according  to 
whether vessels had been taken from patients treated with, or not treated with, an 
ACE inhibitor.  
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2.3  METHODS  FOR  STUDY  OF  EFFECT  OF  RELAXIN  ON  HUMAN 
INTERNAL MAMMARY ARTERIES AND SAPHENOUS VEINS. 
 
2.3.1 PATIENTS 
 
Coronary  artery  bypass  graft  (CABG)  surgery  is  a  common  procedure  at  the 
Western  Infirmary,  with  approximately  1000  operations  performed  each  year. 
Usually distal segments of the left internal mammary artery (IMA) and saphenous 
vein (SV) are surplus to requirement and subsequently discarded. These segments 
can thus be used for scientific research.  
Patients undergoing elective CABG for coronary artery disease were included in 
this study. These patients were invited to consent for the study prior to the CABG 
being performed. The study was fully approved by the West Ethics committee of 
the Western Infirmary, on behalf of the North Glasgow Hospitals NHS Trust. 
Clinical details were recorded from case note examination. A history of current 
cigarette  smoking,  hypertension  (defined  as  either  current  anti-hypertensive 
medication or blood pressure >140/90 mmHg, diabetes mellitus (insulin treated or 
non-insulin  treated)  and  hypercholesterolaemia  (plasma  cholesterol  >5.4)  were 
noted. Information on other current medication was also documented at this point. 
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2.3.2 VESSEL PREPARATION 
 
Distal segments of left internal mammary artery (IMA) and saphenous veins (SV), 
were harvested at the time of routine coronary artery revascularization surgery in 
the Cardiac Surgical Theatre Suites within the Western Infirmary, and surplus to 
requirement. The discarded distal end of the IMA (1–2 cm) and segments of SV 
(1–2 cm) were immediately taken to the laboratory in Krebs –HEPES buffer on ice. 
The blood vessels were then carefully dissected free from connective tissue under 
these  conditions  and  divided  into  4-5mm  segments.  The  vessels  were  then 
incubated in Krebs buffer at pH 7.4 
+ 2 and maintained in atmospheric conditions 
(PO 2 19 
+ 4 kPa; PCO 2 3 
+ 4 kPa) at 37
oC. 
 
2.3.3 ORGAN BATH STUDIES 
 
Some rings were studied immediately, others were stored in PSS overnight. The 
PSS (pH 7.490.1) had the following composition (in mM): 130 NaCl, 4.7 KCl, 14.9 
NaHCO3 , 1.18 KH2 PO4 , 5.5 glucose, 1.17 MgSO4 .7H2 O, 1.6 CaCl2 .2H2 O, 
and 0.03 CaNa2 EDTA. Storage under these conditions had no effect on endothelial 
responses. The vessels were cleaned of connective tissue and cut into 2–3 mm long 
segments. Rings were suspended on wires in 10 ml organ chambers  filled with 
physiological salt solution (PSS), maintained at 37°C, and aerated with a mixture of 
95% O2 -5% CO2 . The rings were connected to force transducers, and changes in 
isometric tension were recorded.    94 
The rings of human IMAs and SVs were equilibrated in the organ baths in PSS 
solution before the protocol was initiated. Optimal tension, defined as the tension at 
which maximum constriction to phenylephrine (PE) occurred, was determined.  
In the series of experiments, cumulative dose-response curves to phenylephrine (10 
-8 -10 
-5 M ITA, 10 
-8 -10
 -5 M SV) were constructed. Baths were washed out and 
the tissues allowed to relax. They were then constricted to their individual EC50 
values for phenylephrine and relaxation to carbachol (10 
-8 – 10 
-5 M) studied. 
Following  normalisation,  the  vessels  were  left  for  a  further  hour.  Potassium 
chloride (KCl) was used as a receptor-independent vascular
 smooth muscle cell 
depolarizing  agent.  At  100mmol/L,  maximal
  contraction  is  obtained.  The 
noradrenaline analogue  PE was used
 to constrict the rings via α-adrenoceptors. 
Carbachol, a stable
 analogue of acetylcholine, was used to relax the rings in an 
endothelium-dependent
  manner via  muscarinic  receptors, resulting in stimulated 
NO
 release. After a plateau contraction had been attained with PE, the vessels were 
incubated for a further 30 minutes in PSS solution prior to the commencement of 
the  concentration-response  curves  (CRC)  incorporated  in  the  study  protocol. 
Arteries  that  were  unable  to  contract  to  either  KPSS  or  phenylephrine  were 
discarded.  
 
Cumulative vasorelaxation curves to relaxin 10
-13M to 10
-7M were constructed in 
rings preconstricted with phenylephrine. Since relaxin is endothelium dependent, 
the calcium ionophore A23187 (CaI) was added to the bath following the CRC. A 
vasorelaxant response of the vessel to CaI  (10
-4M to 10
-2M) confirmed that the   95 
endothelium was intact (as CaI is also endothelium dependent). If there was no 
vasorelaxation response to CaI then we concluded that the endothelium was not 
functionally intact and the vessel was not included in the data. 
 
 
2.4 METHODS FOR  THE STUDY  OF THE PROGNOSTIC EFFECT OF 
RELAXIN  COMPARED  WITH  NT-BNP  IN  PATIENTS  WITH  HEART 
FAILURE. 
 
2.4.1 PATIENTS 
 
Patients taking part in a randomised controlled trial of specialist nurse intervention 
were studied (Blue et al, 2001). Patients admitted to hospital, as an emergency, with 
heart failure due  to  left  ventricular systolic  dysfunction  were  enrolled  in  a  trial 
comparing conventional care to conventional care supplemented by specialist heart 
failure nurse intervention.  Patients were followed for a mean of 12 months after 
randomisation.  Deaths and hospital re-admissions were recorded.  Re-admissions 
were adjudicated by a blinded end-point Committee.  The primary end-point was 
death or readmission with heart failure.  Patients consented to have venous blood 
collected for measurement of neurohumoral factors. 
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2.4.2 ASSAYS 
 
2.4.2.1 NT-pro BNP Assay 
NT-pro BNP was measured in blood samples using a validated and commercially 
available immunoassay (Roche Diagnostics, Germany).  
The  Roche  Elecsys  proBNP  (Roche  Diagnostics,  East  Sussex,  England) 
Immunoassay was used to analyse NT-proBNP (proBNP).   The Elecsys method 
used  was  an  electrochemiluminescent  immunoassay  on  an  Elecsys  2010 
autoanalyser.  This has a within-assay and between-assay confidence variable of 2.7 
and 3.2% respectively.  The measuring range of the assay is 5 – 35,000 pg/ml.  The 
analytical sensitivity of the assay is 5pg/ml.  The diagnostic information quotes the 
cut-off for patients younger than 75 years to be 125 pg/ml and 450pg/ml for those 
75 years and older.  From work conducted on a healthy population, the following 
95
th percentile figures were established as normal ranges dichotomised for age and 
sex (Table 2.1).  An elevated NT-proBNP was taken to be a value greater than the 
95
th percentile for each age and sex category.     
 
Table 2.1  95
th  percentile  according  to  age  and  sex  of  NT-proBNP  for  a 
healthy population   
 
  NT-proBNP concentration pg/ml 
Age (years)  ≤ 64  65-69  70-74  ≥ 75 
Female  213.4  314.2  338.5  355.3 
Male  122.6  112.6  236  295.7   97 
2.4.2.2 Relaxin Assay 
 Plasma relaxin was determined using an ELISA kit (Immundiagnostik, Bensheim, 
Germany). The polyclonal antibody was raised in rabbits. The kit has a detection 
limit of 0.40 pg/ml that was calculated from the mean optical density of the zero 
standard  (measured  in  duplicate),  plus  2  standard  deviations.  The  intra-assay 
coefficient of variation is 9.6% (=18, at 15 pg/ml) and the interassay coefficient of 
variation is 10.2% (=12, at 15 pg/ml). The kit is highly selective for human relaxin 
with cross-reactivity measuring 100% for the H1 form and 100% for the H2 form. 
Cross-reactivity  against  insulin,  insulin-like  growth  factors,  luteinising  hormone 
(LH), follicle stimulating hormone (FSH), and prolactin is less than <0.01%. 
   
2.4.3 STATISTICAL ANALYSIS   
 
Event rates were compared for patients with plasma concentrations of NT-pro BNP 
and relaxin above and below the group median.  As NT-pro BNP concentrations 
above  the  median  were  associated  with  a  significantly  worse  clinical  outcome, 
multivariate analyses were carried out in order to determine whether or not NT-pro 
BNP  was  an  independent  predictor  of  outcome  (death  and  death  or  hospital 
admission for CHF).  Firstly, a univariate analysis was performed using all relevant 
baseline data (e.g. age, sex, NYHA Class, left ventricular function, heart rhythm, 
co-morbidity,  history  of  prior  CHF  hospitalisation,  creatinine  etc)  and  variables 
significantly (p<0.05) associated with outcome were then examined in a stepwise 
multivariate analysis.     98 
2.5  METHODS  FOR  THE  STUDY  OF  THE  TRANSPULMONARY  AND 
TRANSCARDIAC GRADIENTS OF RELAXIN. 
 
2.5.1 PATIENTS 
 
20  consecutive  patients  undergoing  elective  coronary  artery  revascularization 
surgery for coronary artery disease, at the Cardiac Surgical Theatre Suites, within 
the Western Infirmary, were studied.  These patients were invited to consent for the 
study prior to the CABG being performed. The study was fully approved by the 
West Ethics committee of the Western Infirmary, on behalf of the North Glasgow 
Hospitals NHS Trust. 
Clinical details were recorded from case note examination. A history of current 
cigarette  smoking,  hypertension  (defined  as  either  current  anti-hypertensive 
medication or blood pressure >140/90 mmHg, diabetes mellitus (insulin treated or 
non-insulin  treated)  and  hypercholesterolaemia  (plasma  cholesterol  >5.4)  were 
noted. Information on other current medication was also documented at this point. 
Left ventricular systolic function (estimated ejection fraction) as determined by 
Simpson’s biplane method on echocardiography was noted for each patient. 
 
 
 
 
   99 
2.5.2 BLOOD SAMPLING 
 
Immediately prior to institution of cardiopulmonary bypass, blood samples were 
taken by the operating Cardiothoracic Surgeon, in rapid succession, from the aorta, 
coronary sinus, pulmonary artery and pulmonary vein. I then placed the samples 
into chilled tubes and transported them directly to the lab for analysis. 
 
2.5.3 ASSAYS 
 
A  validated  relaxin  immunoassay  was  used  (Immundiagnostik,  Bensheim, 
Germany) as detailed previously (section 2.4.2). 
 
2.5.4 STATISTICAL ANALYSIS 
    
Statistical analysis was performed using a Wilcoxon signed rank test. 
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CHAPTER 3: 
THE COMPARATIVE VASODILATOR ACTION 
OF RELAXIN IN HUMAN RESISTANCE AND 
PULMONARY ARTERIES 
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3.1 Summary  
 
It has been shown recently that relaxin is secreted by the heart. Cardiac mRNA 
expression  and  secretion  of  relaxin  are  increased  in  chronic  heart  failure. 
Circulating concentrations of relaxin are also markedly elevated in heart failure 
in  proportion  to  clinical  severity.  (Dschietzig  et  al,  2001).    As  with  other 
peptides, such as atrial natriuretic peptide and brain natriuretic peptide, cardiac 
relaxin secretion may be a compensatory response in heart failure and relaxin 
may be a circulating vasoactive hormone. This study  examined the effects of 
relaxin in small resistance arteries from the systemic and pulmonary circulations. 
 
3.2 PATIENTS 
 
Thirteen patients with coronary heart disease but normal left ventricular systolic 
function  were  studied.    Lung  tissue  was  obtained  from  another  5  patients 
undergoing pneumonectomy for cancer. 
The study had Ethics Committee approval and patients gave informed consent. 
 
3.3 MATERIALS 
 
Relaxin  was  gifted  by  Connetics  Corporation,  Palo  Alto,  USA.    Experiments 
were  carried  out  in  physiological  salt  solution  (PSS)  with  the  following 
composition  (mM):  NaCI  118.4,  KCI  4.7,  MgSO4II2O  1.2,  KH2PO4  1.2.  Na   102
HCO3 24.9, CaCI2 2.5, glucose 11.1, EDTA 0.023 which gives a pH of 7.4 when 
gassed with a 5% CO2/95% O2 mixture.  A Mulvany-Halpern four-channel wire 
myograph (Danish Myotech, Aarhus, Denmark) was used.  
 
3.4 SYSTEMIC RESISTANCE ARTERY STUDIES 
 
3.4.1 Gluteal biopsy procedure and artery preparation 
Gluteal  biopsies  were  obtained  under  local  anaesthesia  (1%  lidocaine),  as 
previously described (Methods 2.1.3). Resistance arteries (diameter < 300 µm, 
length approximately 2mm), were dissected and mounted in the  myograph as 
previously described. The bath was gassed and heated for the duration of the 
experiment. 
 
3.4.2 Subjects 
Table 3.1 shows the characteristics of the patients studied.  
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Table 3.1. Characteristics of Patients Providing Small Systemic Resistance 
Arteries 
Number of patients  13 
Sex M/F  8/5 
Age, y (range)  67 (55-78) 
Previous MI  4 
Previous CABG  6 
Current smoker  3 
Drug therapy 
-β blocker 
-Aspirin 
-HMG CoA reductase inhibitor 
-ACE inhibitor 
-Calcium channel blocker 
-Diuretic 
-Digoxin 
-Nitrate 
-Nicorandil 
 
11 
13 
13 
6 
2 
4 
3 
5 
2 
Creatinine, µmol/L 
Mean LVEF % (range) 
105
+ 5 
55 (45-70) 
 
M/F indicates male/female; MI indicates myocardial infarction; CABG, coronary 
artery  bypass  grafting;  ACE,  angiotensin-converting  enzyme,  HMG  CoA,  3-
hydroxy-3-methylglutaryl coenzyme A, LVEF, left ventricular ejection fraction. 
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3.5  STUDIES  IN  SMALL  SYSTEMIC  RESISTANCE  ARTERIES  WITH 
INTACT ENDOTHELIUM 
 
3.5.1 Resistance artery diameter 
The mean internal diameter (ID) of the systemic resistance arteries was 283 + 21 
µm.  ACh caused an 88+ 4% reduction in norepinephrine-induced tone, verifying 
the existence of an intact endothelium. 
 
         3.5.2 Response to vasodilators 
Figure 3.1 below shows the vasodilator activity of substance P (n=8), epoprostenol 
(PGI 2) (n=6), ANP (n=6) and relaxin (n=8).  
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Figure 3.1. Cumulative concentration response curves for relaxin, ANP, 
substance P and epoprostenol in small human resistance arteries with intact 
endothelium. 
 
Substance  P,  as  noted  previously,  was  a  powerful  vasodilator.      Relaxin  had 
comparable activity to epoprostenol (prostaglandin I2).  ANP was the weakest of 
the vasodilators studied.   The maximal responses were 88(+5) %, 66(+16) %, 
67(+10) % and 52(+16) %, respectively.    106
A 10% of maximal vasodilator response was achieved with 1x10
-13M substance P, 
2x10
-13M epoprostenol, 1x10
-12M relaxin and 3x10
-10M ANP (P<0.05 for relaxin 
versus ANP). 
   
Figure 3.2.  Cumulative concentration response curve for relaxin compared 
with ANP in small human resistance arteries with intact endothelium. 
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P<0.05   107
3.5.3 Relaxin versus ANP 
   
We found that relaxin is vasoactive at concentrations comparable to those found 
in  chronic  heart  failure.  Mean  plasma  relaxin  concentrations  in  patients  with 
severe chronic heart failure, average 2.5 to 3.34 x 10
-11 mol/L while mean plasma 
ANP concentrations in patients with severe CHF, average 2.5 x 10
-11 mol/L. At 
10
-11 mol/L relaxin caused 26% vasodilation of resistance arteries versus 0.68% 
with the same concentration of ANP. 
 
3.5.4 Procedure for removal of endothelium and experimental protocol in de-
endothelialised vessels. 
 
To gain further mechanistic insight into relaxin, endothelium was mechanically 
removed from a further set of vessels by gently rubbing the luminal side of the 
arterial wall with a human hair (stored in ethanol and rinsed with PSS before use). 
Endothelial removal was confirmed by the lack of relaxation to ACh. A CCRC 
was then constructed with relaxin 10
-13 to 10-
7M.    
 
3.5.5 Response to relaxin in systemic resistance arteries following removal of 
endothelium  
 
Figure 3.3 shows that endothelial rubbing virtually abolished the action of relaxin 
(n=8, p<0.05).   108
 
 
Figure 3.3 Cumulative concentration response curve for relaxin in small 
human resistance arteries with intact endothelium and after removal of the 
endothelium. 
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3.6 PULMONARY RESISTANCE  ARTERY STUDIES. 
 
3.6.1 Artery preparation. 
 
Lung  tissue  was  placed  in  cold  Krebs-buffer  solution.    Pulmonary  resistance 
arteries  (diameter  <  300  µm,  length  approximately  2mm)  were  dissected  and 
mounted in the myograph as described in Methods 2.1.4. 
 
3.6.2 Experimental protocol. 
 
Tension was applied to vessels to give transmural pressures equivalent to 12 – 
16mmHg to simulate in vivo pressures.  Vessels were allowed to equilibrate and 
endothelial integrity was tested, as described above. CCRC were then constructed   
with relaxin 10 
-15 to 10 
-7 M, after preconstricting each vessel with  U46619 – a 
thromboxane A2 mimetic (norepinephrine does not induce sustained constriction 
of human pulmonary vessels). 
Table 3.2 shows the characteristics of the patients studied.   
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Table 3.2. Characteristics of Patients Providing Small Pulmonary Resistance 
Arteries 
Number of patients  5 
Sex M/F  2/3 
Age, y (range)  60 (52-66) 
Previous MI  0 
Previous CABG  0 
Current smoker  1 
Drug therapy 
-β blocker 
-Aspirin 
-HMG CoA reductase inhibitor 
-ACE inhibitor 
-Calcium channel blocker 
-Diuretic 
-Digoxin 
-Nitrate 
-Nicorandil 
 
1 
0 
0 
2 
1 
1 
0 
0 
0 
Creatinine, µmol/L  106
+ 3 
 
M/F indicates male/female; MI indicates myocardial infarction; CABG, coronary 
artery  bypass  grafting;  ACE,  angiotensin-converting  enzyme,  HMG  CoA,  3-
hydroxy-3-methylglutaryl coenzyme A. 
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3.6.3 Response to relaxin in small pulmonary resistance arteries. 
 
The mean ID of the pulmonary vessels (n=5) was 208.8 +10.6µm.  ACh caused a 
76+21% reduction in agonist-induced tone yet relaxin had no effect. 
   
 
3.7 Summary of Chapter Results 
 
In small human systemic resistance arteries, relaxin is a potent vasodilator. 
The vasodilatory action of relaxin is more potent than that of ANP and equipotent 
to epoprostenol. Relaxin’s vasodilatory action, however, is less potent than that of 
substance  P.  In these vessels, the vasodilatory  action of relaxin is endothelium 
dependent. 
In small human pulmonary resistance arteries, relaxin has no effect. 
 
 
These findings have been published.  
C Fisher, M Maclean, I Morecroft, A Seed, F Johnston, C Hillier and J McMurray. 
Is the Pregnancy Hormone Relaxin Also a Vasodilator Peptide Secreted by the 
Heart? Circulation. 2002;106:292-295. 
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CHAPTER 4: 
THE MECHANISM OF ACTION OF RELAXIN 
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          4.1 Summary 
 
Having established that relaxin is a potent, endothelium dependent, vasodilator in 
human  systemic  resistance  arteries,  I  then  went  on,  in  detail,  to  research  its 
mechanism of action.  
 
As described in Section 1.5, the endothelium is an autocrine and paracrine organ 
that  produces  substances  that  decrease  vascular  smooth  muscle  and  inhibit 
inflammation and thrombosis. These substances include nitric oxide, prostacyclin 
and  endothelium  derived  hyperpolarizing  factor  (EDHF).  The  focus  of  the 
experiments in this chapter, therefore, was to block each of the pathways involving 
these substances: nitric oxide, prostacyclin and EDHF, in turn. 
 
Firstly, I investigated whether manipulation of nitric oxide and cyclic GMP would 
have  an  affect  on  relaxin’s  vasodilatory  action.  Secondly,  I  looked  at  whether 
manipulation  of  prostanoids  and  cAMP  altered  relaxin’s  action.  Lastly,  I 
determined whether manipulating EDHF would have an affect on relaxin’s action. 
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4.2 PATIENTS 
 
Patients with coronary heart disease with no history of heart failure were studied.  
Details  of  the  patients  studied  are  given  in  Tables  4.1  and  4.2.  For  reasons 
detailed below, groups were split into those patients taking ACE inhibitors and 
those patients not taking ACE inhibitors. 
 
The study had Ethics Committee approval and patients gave informed consent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
   115
Table 4.1. Characteristics of Patients Providing Small Systemic Resistance 
Arteries On an ACE Inhibitor 
Number of patients  28 
Sex M/F  22/6 
Age, y (range)  61 (44-74) 
Previous MI  11 
Previous CABG  3 
Current smoker  3 
Drug therapy 
-β blocker 
-Aspirin 
-HMG CoA reductase inhibitor 
-ACE inhibitor 
-Calcium channel blocker 
-Diuretic 
-Digoxin 
-Nitrate 
-Nicorandil 
 
24 
28 
27 
28 
7 
6 
0 
5 
5 
Creatinine, µmol/L  109
+ 4 
 
M/F indicates male/female; MI indicates myocardial infarction; CABG, coronary 
artery  bypass  grafting;  ACE,  angiotensin-converting  enzyme,  HMG  CoA,  3-
hydroxy-3-methylglutaryl coenzyme A.  
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Table 4.2. Characteristics of Patients Providing Small Systemic Resistance 
Arteries Not On an ACE Inhibitor 
Number of patients  30 
Sex M/F  23/7 
Age, y (range)  62 (41-80) 
Previous MI  8 
Previous CABG  3 
Current smoker  4 
Drug therapy 
-β blocker 
-Aspirin 
-HMG CoA reductase inhibitor 
-ACE inhibitor 
-Calcium channel blocker 
-Diuretic 
-Digoxin 
-Nitrate 
-Nicorandil 
 
25 
30 
26 
0 
16 
6 
0 
9 
6 
Creatinine, µmol/L  111
+ 5 
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4.3 MATERIALS 
 
Relaxin was gifted by Connetics Corporation, Palo Alto, USA.  Experiments were 
carried out in physiological salt solution (PSS)  with the following  composition 
(mM): NaCI 118.4, KCI 4.7, MgSO4II2O 1.2, KH2PO4 1.2. Na HCO3 24.9, CaCI2 
2.5, glucose 11.1, EDTA 0.023 which gives a pH of 7.4 when gassed with a 5% 
CO2/95% O2 mixture.  A Mulvany-Halpern four-channel wire myograph (Danish 
Myotech, Aarhus, Denmark) was used.  
 
 
4.4 GLUTEAL BIOPSY PROCEDURE AND ARTERY PREPARATION 
 
Gluteal  biopsies  were  obtained  under  local  anaesthesia  (1%  lidocaine),  as 
previously described (Methods 2.1.3). Resistance arteries (diameter < 300 µm, 
length approximately 2mm), were dissected and mounted in the  myograph as 
previously described. The bath was gassed and heated for the duration of the 
experiment. 
 
4.4.1 Resistance Artery Diameter 
The  mean  internal  diameter  of  the  human  small  systemic  resistance  arteries 
studied was 290 ± 25 µ M.  ACh caused a 90 ± 5% reduction in norepinephrine 
induced tone, verifying the existence of an intact endothelium. 
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4.5 EFFECT OF PRIOR TREATMENT WITH AN ACE INHIBITOR 
 
An  unexpected  finding  was  that  prior  treatment  with  an  ACE  inhibitor 
substantially attenuated the vasodilator effect of relaxin (p<0.0001) (Figure 4.1)  
 
Figure 4.1. 
Relaxin Relaxation Curve Comparing COA and CNOA 
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COA = patient on ACE inhibitor 
CNOA = patient not on ACE inhibitor 
   
Consequently, all subsequent analyses were carried out separately, according to 
whether vessels had been taken from patients treated with, or not treated with, an 
ACE inhibitor. 
The results of these analyses will be presented separately. 
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4.6 PATIENTS ON ACE INHIBITORS 
 
4.6.1 Manipulation of Nitric Oxide and cyclic GMP 
 
I) Inhibition of Nitric Oxide Synthase    
 
Both  L-NOARG  and  L-NAME  affected  the  vasodilator  response  to  relaxin  in 
arteries from patients treated with an ACE inhibitor. As each graph demonstrates, 
relaxin’s vasodilator action was enhanced by blocking nitric oxide. This result was 
not expected and indeed was the opposite of what was anticipated (Figures 4.2 and 
4.3). 
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Figure 4.2   
Relaxin Relaxation Curve With L-NOARG (COA)
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Figure 4.3. 
Relaxin Relaxation Curve Incubated with L-NAME (COA)
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p<0.05 
p<0.05   121
II) Inhibition of Soluble Guanylate Cyclase  
 
Prior incubation with ODQ, the soluble guanylate cyclase inhibitor, reduced the 
vasodilator response to relaxin (Figure 4.4) in arteries taken from patients treated 
with an ACE inhibitor (Soluble guanylate cyclase converts GTP to cGMP) 
 
 
Figure 4.4. 
Relaxin Relaxation Curve with ODQ -4M (COA)
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p=0.0009   122
III) Inhibition of cGMP Phosphodiesterase:    
 
Prior  incubation  of  arteries  with  zaprinast,  which  prevents  the  breakdown  of 
cGMP, appeared to mildly enhance the vasodilator response to relaxin in patients 
treated with an ACE inhibitor (figure 4.5). 
 
 
 
Figure 4.5. 
Relaxin Relaxation Curve with Zaprinast (COA)
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4.6.2 Manipulation of Prostanoids and cyclic AMP 
 
I) Inhibition of Cyclo-oxygenase   
 
Indomethacin,  which  inhibits  cyclo-oxygenase,  greatly  reduced  the  vasodilator 
effect of relaxin in arteries obtained from patients taking an ACE inhibitor (figure 
4.6). 
 
 
 
Figure 4.6.  
Relaxin Relaxation Curve with Indomethacin (COA)
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II) Inhibition of cAMP Phosphodiesterase    
 
In  arteries  from  patients  treated  with  an  ACE  inhibitor,  prior  incubation  with 
milrinone  (which  prevents  the  breakdown  of  cAMP)  enhanced  the  vasodilator 
response to relaxin (Figure 4.7). 
 
 
 
Figure 4.7. 
 
Relaxin relaxation Curve With Milrinone (COA)
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4.6.3 Inhibition of Endothelium-Derived Hyperpolarising Factor 
 
Prior incubation with the EDHF inhibitors, charybdotoxin and apamin, in arteries 
from patients treated with an ACE inhibitor (Figure 4.8), enhanced the vasodilator 
response of relaxin. (Charybdotoxin and apamin block calcium activated potassium 
channels).  
 
Figure 4.8. 
Relaxin Relaxation Curve With Apamin + Charyb (COA)
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4.7 PATIENTS NOT ON ACE INHIBITORS 
4.7.1 Manipulation of Nitric Oxide and cyclic GMP 
 
I) Inhibition of Nitric Oxide Synthase  
 
Inhibition  of  nitric  oxide  synthase  with  L-NOARG  and  L-NAME  reduced  the 
vasodilator response to relaxin in arteries taken from patients not taking an ACE 
inhibitor (figure 4.9 and figure 4.10). 
 
Figure 4.9. 
Relaxin Relaxation Curve With L-NOARG (CNOA)
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Figure 4.10. 
 
Relaxin Relaxation Curve with L-NAME (CNOA)
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II) Inhibition of Soluble Guanylate Cyclase  
  
Prior  incubation  with  ODQ  greatly  reduced  the  vasodilator  response  to  relaxin 
(Figure 4.11) in arteries taken from patients not treated with an ACE inhibitor. 
(Soluble guanylate cyclase converts GTP to cGMP). 
 
Figure 4.11. 
Relaxin Relaxation Curve With ODQ -4M (CNOA)
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III) Inhibition of cGMP Phosphodiesterase   
 
Prior  incubation  of  arteries  with  zaprinast  (which  prevents  cGMP  breakdown) 
reduced the vasodilator response to relaxin in patients not taking an ACE inhibitor 
(figure 4.12). 
 
Figure 4.12. 
Relaxin Relaxation Curve with Zaprinast (CNOA)
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4.7.2 Manipulation of Prostanoids and cyclic AMP 
 
I) Inhibition of Cyclo-oxygenase   
 
In arteries from patients not treated with an ACE inhibitor, prior incubation with 
indomethacin reduced the vasodilator response to relaxin (Figure 4.13). 
 
Figure 4.13. 
Relaxin Relaxation Curve with Indomethacin (CNOA)
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II) Inhibition of cAMP phosphodiesterase   
 
In arteries from patients not treated with an ACE inhibitor, prior incubation with 
milrinone  (which  prevents  cAMP  breakdown)  had  no  effect  on  the  vasodilator 
response to relaxin (Figure 4.14). 
 
Figure 4.14. 
Relaxin Relaxation Curve with Milrinone (CNOA)
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4.7.3 Inhibition of Endothelium-Derived Hyperpolarising Factor 
 
Prior incubation with the EDHF inhibitors, charybdotoxin and apamin, in arteries 
from patients not treated with an ACE inhibitor, had no effect on the vasodilator 
response  of  relaxin  (Figure  4.15).  (Charybdotoxin  and  apamin  block  calcium 
activated potassium channels).  
 
Figure 4.15. 
Relaxin Relaxation Curve With Apamin + Charyb (CNOA) 
0
10
20
30
40
50
60
70
80
90
100
-14 -13 -12 -11 -10 -9 -8 -7 -6
Log Relaxin
%
 
R
e
l
a
x
a
t
i
o
n CNOA n=28
CNOA Apamin
+Charyb.-7M n=8
 
 
 
 
 
 
 
 
p=n.s.   133
4.8 Summary of Chapter Results 
 
4.8.1 PATIENTS ON ACE INHIBITORS 
 
1)  Manipulation of prostanoids and cyclic AMP. 
 
In patients treated with an ACE inhibitor, manipulation of prostanoids and cAMP  
is  important.  Blocking  the  prostanoid  pathway  with  indomethacin  blocked 
relaxin’s  vasodilatory  action.  By  preventing  the  breakdown  of  cAMP  with 
milrinone, relaxin’s vasodilatory action was enhanced. 
 
2)  Manipulation of cyclic GMP  
 
Manipulation of the cyclic GMP second messenger system may be important in 
patients treated with an ACE inhibitor. By inhibiting guanylate cyclase with ODQ 
and  thus  the  conversion  of  GTP  to  cGMP,  relaxin’s  vasodilatory  effect  was 
reduced.  In  keeping  with  this,  preventing  the  breakdown  of  cyclic  GMP  with 
zaprinast, did enhance (although mildly) relaxin’s vasodilatory effect. However, 
these  findings  were  at  supraphysiological  levels  of  relaxin  and  so  may  not  be 
clinically relevant. 
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3)  Manipulation of nitric oxide and  4) Manipulation of EDHF 
 
Manipulation of the nitric oxide pathway by blocking nitric oxide with L-NOARG 
and L-NAME and EDHF pathway by blocking potassium channels with apamin 
and charybdotoxin had curious effects, in patients taking  an ACE inhibitor, by 
enhancing relaxin’s vasodilatory action which is the opposite of what one might 
expect. The results for L-NOARG and L-NAME were at supraphysiological levels 
of relaxin and may not be clinically relevant. 
 
 
4.8.2 PATIENTS NOT ON ACE INHIBITORS 
 
1)  Manipulation of nitric oxide  
 
Manipulation of the nitric oxide pathway is important. In patients not treated with 
an ACE inhibitor, blocking nitric oxide synthesis with L-NAME and L-NOARG, 
resulted in reduced vasorelaxation with relaxin. 
 
2)  Manipulation of cGMP  
 
Manipulation  of  the  cGMP  second  messenger  system  by  inhibiting  guanylate 
cyclase (with ODQ) and thus the conversion of GTP to cGMP, is also important in 
patients  not  treated  with  an  ACE  inhibitor.  ODQ  greatly  reduced  relaxin’s   135
vasodilatory  action.  However,  preventing  the  breakdown  of  cyclic  GMP  with 
zaprinast  did not  enhance  relaxin’s  vasodilatory  effect  and if  anything  reduced 
vasodilation. 
 
 
 
 
3)  Manipulation of prostanoids and cyclic AMP 
 
Manipulation  of  prostanoids  by  blocking  prostacyclin  with  indomethacin  in 
patients not treated with an ACE inhibitor, reduced relaxin’s vasodilatory action. 
However, preventing the breakdown of cAMP with milrinone had no effect on the 
vasodilatory action of relaxin in these patients. 
 
 
4)  Manipulation of EDHF 
 
Manipulation of the EDHF pathway by blocking potassium channels with apamin 
and charybdotoxin respectively had no effect on relaxin’s vasodilatory action in 
patients not treated with an ACE inhibitor.  
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CHAPTER 5: 
RELAXIN IN HUMAN INTERNAL MAMMARY 
ARTERIES AND SAPHENOUS VEINS. 
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5.1 Summary 
 
Having shown that in small human systemic resistance arteries, relaxin is a potent 
vasodilator, I was keen to establish whether the same were true in larger calibre 
arteries. Also, the action of relaxin in the venous system has not been investigated, 
previously. In this chapter, therefore, the results of this investigation into the action 
of relaxin in human internal mammary arteries (IMA) and saphenous veins (SV) 
are reported. 
 
 
5.2 PATIENTS 
 
IMA and SV from ten patients with coronary heart disease undergoing CABG 
were studied, as described in Methods 2.3.1 
 
 
Table 5.1 below gives the characteristics of the patients involved in the study. 
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Table 5.1. Characteristics of Patients Providing Internal Mammary Arteries 
and Saphenous Veins 
 
Number of patients  10 
Sex M/F  10/0 
Age, y (range)  68 (54-78) 
Previous MI  4 
Previous CABG  0 
Current smoker  1 
Drug therapy 
-β blocker 
-Aspirin 
-HMG CoA reductase inhibitor 
-ACE inhibitor 
-Calcium channel blocker 
-Diuretic 
-Digoxin 
-Nitrate 
-Nicorandil 
 
8 
10 
8 
2 
8 
2 
1 
8 
5 
Creatinine, µmol/L  120
+ 8 
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M/F indicates male/female; MI indicates myocardial infarction; CABG, coronary 
artery  bypass  grafting;  ACE,  angiotensin-converting  enzyme,  HMG  CoA,  3-
hydroxy-3-methylglutaryl coenzyme A.  
 
The study had Ethics Committee approval and patients gave informed consent. 
 
5.3 MATERIALS 
Relaxin  was  gifted  by  Connetics  Corporation,  Palo  Alto,  USA.    Experiments 
were  carried  out  in  physiological  salt  solution  (PSS)  with  the  following 
composition  (mM):  NaCI  118.4,  KCI  4.7,  MgSO4II2O  1.2,  KH2PO4  1.2.  Na 
HCO3 24.9, CaCI2 2.5, glucose 11.1, EDTA 0.023 which gives a pH of 7.4 when 
gassed with a 5% CO2/95% O2 mixture.  
 
5.4 ORGAN BATH TECHNIQUE 
 
Rings of IMA and SV were set up in organ baths as described in Methods 2.3.2. 
Cumulative  response  curves  were  then  constructed  to  relaxin  in  vessels  pre-
constricted with phenylephrine. Since relaxin is endothelium dependent, an intact 
endothelium  was  verified,  following  the  CCRC,  if  relaxation  to  the  calcium 
ionophore  (CaI)  A23187  occurred.  If  no  relaxation  to  CaI  occurred  then  the 
vessel  was  not  included  in  the  data.  IMA  from  12  patients  and  SV  from  14 
patients were rejected because the endothelium was not intact. 
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5.5 RELAXIN CUMULATIVE CONCENTRATION RESPONSE CURVE 
IN HUMAN IMA 
 
In  human  internal  mammary  arteries,  no  significant  difference  was  found 
between relaxin and the control (vehicle) i.e. relaxin did not cause significant 
relaxation in these large calibre arteries (Figure 5.1). 
 
Figure 5.1. 
Relaxin Relaxation Curve For IMA
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5.6 RELAXIN CUMULATIVE CONCENTRATION RESPONSE CURVE 
IN HUMAN LSV 
 
In human long saphenous veins, no significant difference  was found between 
relaxin and the control (vehicle) i.e. relaxin did not cause significant relaxation in 
these large calibre veins (Figure 5.2). 
 
Figure 5.2. 
Relaxin Relaxation Curve for LSV
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5.7 Summary of Chapter Results 
 
Relaxin  was  not  found  to  cause  relaxation  in  human  large  calibre  vessels  i.e 
internal  mammary  arteries  or  long  saphenous  veins  harvested  at  the  time  of 
coronary artery bypass grafting. 
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CHAPTER 6: 
RELAXIN COMPARED WITH NT-BNP IN 
HEART FAILURE 
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6.1 Summary  
 
Relaxin has been shown to be a powerful systemic arterial vasodilator released 
from the heart. (Fisher et al, 2002). One recent report has shown increased cardiac 
relaxin  release  and  elevated  plasma  relaxin  concentrations  in  heart  failure. 
(Dschietzig et al, 2001).  Consequently, it has been postulated that relaxin, like the 
natriuretic peptides, may be secreted as a compensatory neuroendocrine response 
in  heart  failure.  ((Dschietzig  et  al,  2001),  (Fisher  et  al,  2002).      With  other 
pathophysiologically  important  neurohumoral  mediators  there  is  a  clear 
relationship to outcome in heart failure, whereby higher plasma concentrations, 
indicating  greater  neurohumoral  activation,  are  associated  with  a  worse 
prognosis.(Francis  et  al,  1984),  (Cohn  et  al,  1984),  (Swedberg  et  al,  1990). 
Consequently,  we  have  examined  the  relationship  between  plasma  relaxin 
concentration and clinical events in patients with chronic heart failure (CHF).  As a 
“positive control”, we also examined the prognostic importance of N-terminal pro 
B-type natriuretic peptide (NT pro BNP) in the same patients (Hunt et al, 1995). 
 
 
 
 
 
 
   145
 
6.2 PATIENTS 
 
Patients taking part in a randomised controlled trial of specialist nurse intervention 
were studied.  This trial has been described in detail elsewhere (Blue et al, 2001).  
Briefly, patients admitted to hospital, as an emergency, with heart failure due to 
left  ventricular  systolic  dysfunction  were  enrolled  in  a  trial  comparing 
conventional  care  to  conventional  care  supplemented  by  specialist  heart  failure 
nurse  intervention.    Patients  were  followed  for  a  mean  of  12  months  after 
randomisation.  Deaths and hospital re-admissions were recorded.  Re-admissions 
were adjudicated by a blinded end-point Committee.  The primary end-point was 
death or readmission with heart failure.  Patients consented to have venous blood 
collected for measurement of neurohumoral factors. 
Of the 165 patients randomised, plasma NT-pro BNP and relaxin concentrations 
were available in 87.   
Details of these patients are given in Table 6.1 below. 
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Table 6.1.  Characteristics of  Patients Studied  
 
Number of patients  87 
Age (range)  75(51-93) 
Sex (male/female)  51/36 
Current angina  38 
Previous MI  40 
Diabetes  13 
COPD  24 
AF  25 
Beta-blocker  9 
ACE inhibitor  37 
Diuretic  60 
HMG CoA reductase 
inhibitor 
2 
Calcium channel 
blocker 
20 
Digoxin  17 
Nitrate  12 
Aspirin  43 
Warfarin  9 
Admission NYHA class 
II 
III 
IV 
 
21 
28 
38 
Creatinine µmol/l  132+/-7.2   147
 
MI indicates myocardial infarction; COPD, chronic obstructive pulmonary disease; 
AF,  atrial  fibrillation;  ACE,  angiotensin-converting  enzyme,  HMG  CoA,  3-
hydroxy-3-methylglutaryl coenzyme A and NYHA, New York Heart Association. 
 
 
 
6.3 NT-pro BNP CONCENTRATIONS DETECTED IN PATIENTS 
 
The median (range) plasma NT-pro BNP concentration was marked elevated at 
2994 (134-35,000) pg/ml compared to normal (< 334 pg/ml for females and <227 
pg/ml for males).   
Plasma NT-pro BNP was a predictor of both death or heart failure hospitalisation 
and death (Figures 6.1 and 6.2).  Of patients with NT-pro BNP above the median 
concentration (n=43), 23 (53%) died and 30 (70%) died or were hospitalised with 
CHF.  For those with NT- pro BNP concentrations below the median (n=44), these 
proportions were 5 (11%) and 12 (27%) (p<0.0001 for death, and p<0.0001 for 
death or CHF hospitalisation). 
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Figure 6.1 Time to death in patients with plasma NT pro BNP concentrations 
above and below the median 
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Figure 6.2.  Time to death or hospital admission for heart failure in patients 
with      plasma NT pro BNP concentrations above and below the median. 
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In the multivariate analysis, plasma NT pro BNP concentration was a significant, 
independent predictor of death or CHF hospitalization (odds ratio 4.15, p=0.003) 
and  of  death  alone  (odds  ratio  2.22,  p=0.03).  Details  of  the  univariate  and 
multivariate analyses are given below. 
 
Univariate analyses 
An  increased  risk  of  death  was  conferred  by  having  a  plasma  NT-proBNP 
concentration above the median value (OR 8.3±4.7, 95% CI 2.8,25.1; P<0.0001) or 
increasing plasma creatinine concentration (R
2=0.05, P=0.04). An increased risk of 
death was also conferred by having COPD (OR 2.9±1.5, 95% CI 1.1,7.8; P=0.031), 
a  history  or  previous  hospitalisation  for  CHF  (OR  2.6±1.2,  95%  CI  1.0,  6.5; 
P=0.043).  A  reduced  risk  of  death  was  associated  with  the  presence  of  atrial 
fibrillation (OR 0.2±0.1, 95% CI 0.05, 0.7; P=0.015).  
An increased risk of death or CHF hospitalisation was associated with having a 
plasma  NT-proBNP  concentration  above  the  median  value  (OR  8.8±4.4,  95% 
CI3.3,23.2;  P<0.0001),  increasing  plasma  creatinine  concentration  (R
2  =  0.06; 
P=0.023), the presence of valve disease (OR 3.6±2.3, 95% CI 1.0,12.5; P=0.041). 
A reduced risk of death was associated with the presence of atrial fibrillation (OR 
0.4±0.2, 95% CI 0.1, 1.0; P=0.049). 
 
Multivariate analyses 
The results of the multivariate analyses are detailed below.    151
MULTIVARIATE  ANALYSIS  FOR  DEATH,  BASED  ON  FINDINGS  FROM 
UNIVARIATE ANALYSES. 
Outcome variable: death (DEATH), n=87 
------------------------------------------------------------------------------ 
Covariate                  n        Odds Ratio      P>|z|  (95% Conf. Interval) 
------------------------------------------------------------------------------ 
NT-proBNP                                         
  per S.D. (=  6409)  87           2.220        0.029  (1.179 to 4.603) 
CREATININE                                      
  per S.D. (= 67.31)  87           1.110        0.745  (0.593 to 2.078) 
AF                                          
     0*                    60                1 
     1                      25           0.240        0.053  (0.057 to 1.019) 
COPD                                       
     0*                    61                1 
     1                      24           2.011        0.239  (0.628 to 6.437) 
CHFADMISSION                                      
     0*                    47                1 
     1                      38           1.926        0.263  (0.612 to 6.060) 
 
Plasma NT-proBNP was found to be an independent predictor of death (OR 2.2, 
95% CI1.2,4.6; P=0.03).  
 
MULTIVARIATE  ANALYSIS  FOR  DEATH/CHF  ADMISSION  BASED  ON 
FINDINGS FROM UNIVARIATE ANALYSES 
 
Outcome variable: DEATH/CHF, n=87, using standard deviation for NT-proBNP 
and CREATININE 
------------------------------------------------------------------------------ 
Covariate                    n        Odds Ratio      P>|z|  (95% Conf. Interval) 
------------------------------------------------------------------------------ 
NT-proBNP                                         
  per S.D. (=  6409)     87           4.152         0.003  (1.784 to 12.028) 
 
CREATININE                                       
  per S.D. (= 67.31)       87           1.061         0.873  (0.516 to 2.178) 
AF                                          
     0*                    60                1 
     1                      25           0.426         0.163  (0.128 to 1.415) 
VALVEDISEASE                                        
     0*                    70                1 
     1                      15           2.891         0.185  (0.601 to 13.902) 
 
NT-proBNP was an independent predictor of death/CHF hospitalisation (OR 4.152 
1.7 to 12.0; P=0.003).  
   152
 
6.4 RELAXIN CONCENTRATIONS DETECTED IN PATIENTS. 
 
The median (range) plasma relaxin concentration was also markedly elevated at 89 
(11-644) pg/ml compared to normal (< 2 pg/ml).  However, in contrast to NT pro 
BNP, there was no relationship between relaxin and outcome (Figures 6.3 and 6.4).  
Of those patients with a relaxin concentration above the median (n=42), 13 (31%) 
died and 20 (48%) died or were hospitalised.  These proportions for patients with a 
plasma  relaxin  concentration  below  the  median  (n=45)  were  15  (33%)  and  22 
(49%)  (p=0.76 for death and p=0.84 for death or CHF hospitalisation). Plasma 
relaxin concentration was not a significant predictor of outcome in the univariate 
analysis. 
There was no correlation between plasma concentrations of relaxin and NYHA 
functional class (as a marker of severity of heart failure). 
 
There was no correlation between plasma concentrations of relaxin and those of 
NT-proBNP (Figure 6.5). 
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Figure 6.3.  Time to death in patients with plasma relaxin concentrations 
above and below the median. 
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Figure 6.4. Time to death or hospital admission for heart failure in patients 
with plasma relaxin concentrations above and below the median. 
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Figure 6.5. Correlation plot for NT pro BNP and relaxin concentrations. 
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6.5 Summary of Chapter Results. 
 
NT-pro BNP is predictive of both death and death or readmission with worsening 
heart failure. 
We  have  shown  that  NT-pro  BNP  is  a  powerful  and  independent  predictor  of 
outcome in chronic heart failure (CHF). 
Although plasma levels of relaxin were elevated in patients with CHF, it is not 
predictive of outcome. 
 
 
 
 
 
This work has been published. 
C  Fisher,  C  Berry,  L  Blue,  J  J  Morton,  J  McMurray.  N-terminal  pro  B  type 
natriuretic  peptide,  but  not  the  new  putative  cardiac  hormone  relaxin,  predicts 
prognosis in patients with chronic heart failure. Heart 2003; 89:879-881. 
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CHAPTER 7: 
TRANSPULMONARY AND TRANSCARDIAC 
GRADIENT OF RELAXIN 
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7.1 Summary 
 
Relaxin has only lately been shown to have renal and haemodynamic actions.  
Relaxin  may also be secreted by the heart, at least when it is failing (Dschietzig 
et al, 2001) Plasma relaxin concentrations are elevated in chronic heart failure 
(CHF) and myocardial expression of the H1 and H2 relaxin gene is increased in 
proportion to the severity of CHF.  Whether the heart is a source of relaxin when 
cardiac contractility is preserved is unknown.  The lungs are commonly involved 
in  the  clearance  or  secretion  of  vasoactive  peptides  but  their  role  in  relaxin 
metabolism is unknown.  The aim of this study was to measure trans-cardiac and 
trans-pulmonary  relaxin  gradients  in  subjects  with  preserved  left  ventricular 
ejection fraction (LVEF).  Patients undergoing coronary artery bypass grafting 
(CABG) were studied as both pulmonary and cardiac arterial inflow and venous 
effluent can be readily sampled. 
Our study had Ethics approval. 
   
7.2 PATIENTS 
20  consecutive  patients  were  studied.    Immediately  prior  to  institution  of 
cardiopulmonary bypass, blood samples were taken into chilled tubes, in rapid 
succession, from the aorta, coronary sinus, pulmonary artery and pulmonary vein. 
A  validated  relaxin  immunoassay  was  used  (Immundiagnostik,  Bensheim, 
Germany). Statistical analysis was performed using a Wilcoxon signed rank test. 
Patient characteristics are shown in Table 7.1 below.   159
Table 7.1. Characteristics of Patients Studied. 
male/female  (n=14/6) 
 
mean age (range)  62 (44 – 74) 
 
mean LVEF % (range)  55 (25 – 70) 
 
medical history 
•  hypertension 
•  diabetes mellitus 
•  prior MI 
•  asthma 
 
4 
3 
7 
2 
 
current smoker  3 
 
medication 
•  beta-blocker 
•  ACE inhibitor 
•  CCB 
•  long acting nitrate 
•  nicorandil 
•  HMG  CoA  reductase 
inhibitor 
•  diuretic 
 
   160
CCB       = calcium channel blocker 
HMG CoA    = 3-hydroxy-3-methylglutaryl coenzyme A 
LVEF      = left ventricular ejection fraction 
   
 
 
 
7.3 RESULTS. 
 
7.3.1 Transcardiac Gradient of Relaxin. 
 
There was a decrement in the concentration of relaxin between aorta and coronary 
sinus in 16 of the 20 subjects studied, suggesting cardiac extraction of relaxin.  
The mean (SD) concentration fell from 38.1(61.3) to 32.8(57.8) pg/ml (p<0.04).   
No characteristic differentiated the 16 patients with cardiac extraction of relaxin 
from the remaining four (Figure 7.1). 
 
7.3.2 Transpulmonary Gradient of Relaxin. 
 
There was no trans-pulmonary gradient in relaxin concentration.  The mean (SD) 
concentration  in  the pulmonary  artery  was  42.0  (68.3)  pg/ml  versus  41.8(69.1) 
pg/ml in the pulmonary vein (p=n.s). (Figure 7.2).   161
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7.4 Summary of Chapter Results. 
 
In patients with coronary disease but without CHF, there is net cardiac extraction 
of relaxin in contrast to reported secretion in CHF.  In patients without CHF there 
is no transpulmonary gradient in relaxin. 
 
 
 
 
 
This work has been published. 
C  Fisher,  S  Al-Benna,  A  Kirk,  JJ  Morton,  JJV  McMurray.  Transcardiac  and 
transpulmonary  gradients  in  the  putative  new  cardiovascular  hormone  relaxin. 
Heart 2003;89:789-790. 
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CHAPTER 8: 
DISCUSSION 
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8.1 COMPARATIVE POTENCY OF RELAXIN 
 
8.1.1 Relaxin as a Systemic Vasodilator 
 
Our findings show that relaxin is a more potent arterial vasodilator than ANP, also 
secreted by the heart.  It had been suggested that relaxin might exert its systemic 
vasodilator  effects  by  stimulating  the  secretion  of  ANP  (Toth  et  al,  1996). 
However, our results show that relaxin is a vasodilator in its own right. 
Furthermore, relaxin is vasoactive at concentrations comparable to those found in 
CHF.  Mean plasma relaxin concentrations in patients with severe CHF average 
2.5 – 3.34 x 10 
-11 M while mean plasma ANP concentrations in patients with 
severe CHF, average 2.5 x 10
-11 M. At 10 
-11 M, relaxin caused 26 % vasodilation 
of resistance arteries (versus 0.68 % with the same concentration of ANP).   
The potency of relaxin is impressive.  It is equipotent to epoprostenol, a substance 
regarded  as  a  powerful  vasodilator  and  used  therapeutically  in  cardiovascular 
disease  (Kieler-Jensen  et  al,  1995).  Of  course,  epoprostenol  is  a  particularly 
effective pulmonary vasodilator whereas relaxin seems to be devoid of this action. 
 
8.1.2 Relaxin is Endothelium Dependent 
 
We  also  found  that  relaxin  induced  vasodilation  is  endothelium  dependent.  
Removal of the endothelium almost abolished its effect.  This is in keeping with 
the observation that relaxin increases nitric oxide (NO) in cultured vascular smooth   166
muscle  cells  from  bovine  aortae  (Bani  et  al,  1998).
  Similarly,  NO  inhibition 
abolished the increase in renal plasma flow induced by relaxin in rats (Danielson, 
1999).      Relaxin  also  increases  coronary  blood  flow  in  experimental  animals 
through NO (Bani, 1997). 
 
8.1.3 Relaxin Does Not Vasodilate all Arteries. 
 
Interestingly, relaxin does not seem to vasodilate all arteries.  Human relaxin did 
not  dilate  human  myometrial  and  uteroplacental  arteries  pre-contracted  with 
norepinephrine, endothelin or U46619 (Petersen et al, 1991).  Similarly, porcine 
relaxin has no effect on human umbilical arteries pre-contracted with potassium 
chloride or serotonin (Dombrowski et al, 1986).   This suggests that relaxin does 
not act as a vasodilator in the placental-fetal circulation.  We found that relaxin is 
inert in preconstricted human pulmonary resistance arteries, in contrast to systemic 
vessels.  This may reflect differing relaxin receptor distribution in the circulation, 
as the nitric oxide vasodilator pathway was functionally intact in these pulmonary 
vessels (Bathgate et al, 2002). It should also be noted, however, that the sample of 
patients providing small pulmonary resistance arteries was small (n=5) and 2 out of 
5  patients  were  taking  ACE  inhibitors  which  may  have  influenced  the  overall 
result. 
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8.1.4 Other Actions of Relaxin in Cardiovascular Disease 
 
Relaxin could have other potentially favourable vascular and non-vascular actions 
in cardiovascular disease.    For example, relaxin increases vascular endothelial 
growth  factor,  (Unemori  et  al,  1999)  antagonises  the  vasoconstrictor  action  of 
other peptides such as angiotensin II (Massicotte et al, 1989) and inhibits collagen 
synthesis/increases collagen breakdown (Qin et al, 1997).   The last action, key to 
the pelvic remodeling effect of relaxin, could also be important in cardiac and 
vascular remodeling.   In addition, relaxin has also been reported to protect against 
experimental ischemia-reperfusion injury (Bani 1997).   
 
Though  the  true  vaso-regulatory  role  of  relaxin  can  only  be  assessed  using  an 
antagonist, it does seem to be more potent than ANP, a hormone that circulates at a 
similar  concentration and the  inhibition of  which  leads  to  vasoconstriction  and 
other potentially adverse cardiovascular effects (Drexler et al, 1990).  
 
8.1.5 Summary 
 
In summary, we have shown that relaxin, a hormone now known to be secreted by 
the  heart,  is  a  potent  vasodilator  of  small  systemic  resistance  arteries  at 
pathophysiological concentrations and that this action is endothelium dependent.   
Relaxin  is  not,  however,  a  pulmonary  vasodilator.      The pleiotropic  actions  of   168
relaxin suggest that its potential role in cardiovascular regulation merits further 
investigation. 
 
 
 
 
 
8.2  THE MECHANISM OF ACTION OF RELAXIN 
 
This series of experiments, in conjunction with our prior observations, suggests 
that the vasodilator action of relaxin is endothelium-dependent in small resistance 
arteries and involves both NO-dependent and NO-independent cyclic GMP and 
prostanoid-dependent cyclic AMP second messenger pathways (though the latter 
was only  clearly revealed in vessels taken  from patients treated with  an ACE 
inhibitor).  
 
8.2.1  In Patients Not Treated with an ACE inhibitor. 
 
In patients not treated with an ACE inhibitor, the vasodilatory action of relaxin 
appears to be mediated via the nitric oxide pathway since both L-NAME and L-
NOARG  reduced  relaxin’s  action.  In  keeping  with  this,  by  blocking  the 
conversion  of  GTP  to  cGMP  with  the  guanylate  cyclase  inhibitor,  ODQ,  the 
vasodilatory action of relaxin was reduced. However, preventing the breakdown   169
of cGMP, with the cGMP phosphodiesterase inhibitor, zaprinast did not augment 
relaxin’s vasodilatory action. 
  
The Bani group in recent years has provided increasing evidence that relaxin can 
act on several of its targets by increasing the expression and/or activity of nitric 
oxide  synthase  (NOS)  isoenzymes,  thereby  promoting  the  generation  of  nitric 
oxide (NO). In 1994, Masini et al, showed that the relaxin attenuated calcium 
ionophore-induced  granule  exocytosis  by  isolated  rat  serosal  mast  cells,  was 
mediated by nitric oxide (Masini et al, 1994).  
 
This group then went on to show the existence of a relaxin- NO pathway causing 
increased levels of cGMP in rat and guinea pig hearts (Bani-Sacchi et al, 1995), in 
human and rabbit platelets (Bani et al, 1995a), in human breast cancer cells (Bani 
et al, 1995b) and in mouse small bowel (Bani et al, 2002). The NO synthase 
involved depends on the cell type under investigation. In the mouse uterus, relaxin 
causes  up-regulation of  NOS-III  expression  in  epithelium,  glands,  endometrial 
stromal cells and myometrium while leaving inducible NOS (NOS II) expression 
unaffected (Bani et al, 1999). However, in rat coronary endothelial cells (Failli et 
al, 2002) and in bovine aortic smooth muscle cells (Bani et al, 1998), relaxin 
promoted expression and activity of the inducible NO synthase (NOS II) with 
negligible effects on NOS-III. 
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The protective effect of relaxin in cardiac anaphylaxis involves an up-regulation 
of the NO pathway (Ndisang et al, 2001), (Masini et al, 2002). 
 
In  this  group  of  patients,  not  treated  with  an  ACE  inhibitor,  the  prostacyclin 
pathway  also  appears  to  be  important  since  the  cyclo-oxygenase  inhibitor, 
indomethacin, reduced the vasodilatory action of relaxin. As previously described, 
prostacyclin activates adenylate cyclase to produce cAMP.  When we used the 
cAMP  phosphodiesterase  inhibitor,  milrinone,  to  prevent  cAMP  breakdown, 
however,  the  vasodilatory  action  of  relaxin  was  not  augmented.  The  EDHF 
pathway does not appear to be important in this group of patients. 
 
 
8.2.2  In Patients Treated with an ACE inhibitor. 
 
The  most  surprising  finding  of  this  study  was,  however,  that  ACE  inhibitor 
treatment substantially blocked the vasodilator action of relaxin (and revealed a 
second prostanoid-cAMP dependent vasodilator mechanism of action of relaxin). 
By  discovering  that  the  mechanism  of  action  of  relaxin  in  these  patients  is 
different to its action in those patients not treated with ACE inhibitors, we have 
shown that the prostacyclin pathway and the cAMP second messenger pathway 
are  also  important.  Indomethacin  blocked  relaxin’s  action  while  milrinone,  by 
preventing cAMP breakdown, enhanced the vasodilatory action of relaxin in this 
group of patients.    171
 
The cGMP second messenger pathway may also be important in these patients. 
By blocking conversion of GTP to cGMP, ODQ reduced relaxin’s action while 
preventing cGMP breakdown with zaprinast, enhanced relaxin’s action. These 
findings were at supraphysiological levels of relaxin, however, and so may not be 
clinically relevant. 
 
Blocking the NO and EDHF pathways had a curious effect, though as rather than 
reducing the vasodilatory action of relaxin as expected, its vasodilatory effect 
was actually enhanced in patients treated with an ACE inhibitor. Again, it should 
be  noted  that  blocking  of  the  NO  pathway  causing  enhancement  of  relaxin’s 
vasodilatory  action  was  found  at  high  doses  i.e.  supraphysiological  levels  of 
relaxin and so may not be clinically relevant. 
 
 
Why ACE inhibitor treatment should block the effect of relaxin is unknown and 
can only be speculated about.  Of note, the other patient characteristics in the 
ACEI treated group and the non-ACEI treated group are very similar i.e. it does 
appear to be purely an ACE inhibitor effect. ACE inhibitors do, however, up-
regulate the endothelium-vascular smooth muscle nitric oxide-cGMP pathway in 
human arteries.  If it was already substantially activated in our patients taking an 
ACE  inhibitor,  there  may  be  little  remaining  potential  for  relaxin  to  further 
stimulate  this  pathway.    This  circumstance  may,  however,  have  allowed   172
alternative vasodilator pathways to be revealed.  This is indeed what our studies 
with indomethacin and milrinone seem to show.  In vessels taken from patients 
treated with an ACE inhibitor, indomethacin blocked the vasodilator action of 
relaxin whereas milrinone enhanced it.  This suggests that relaxin can also act 
through a prostanoid-cAMP pathway in small human resistance arteries.  
The recent findings from PERTINENT, a substudy of the EUROPA study which 
demonstrated reduction in cardiovascular mortality and myocardial infarction in 
patients  with  stable  coronary  artery  disease  taking  the  ACEI  perindopril, 
demonstrated up-regulation of the nitric oxide pathway via bradykinin (Ceconi et 
al,  2007).  In  this  study,  the  effect  of  perindopril  on  endothelial  function  was 
determined  by  cultivating  in  vitro  human  umbilical  vein  endothelial  cells 
(HUVECs). Incubation of HUVECs with serum taken at baseline from patients 
with  CAD  showed  a  significant  down-regulation  of  endothelial  nitric  oxide 
synthase (eNOS) protein expression and activity (-26% and -30%, respectively; 
both p<0.01 compared with incubation with serum from the control group). At 1 
year, the down-regulation of eNOS protein expression and activity was modulated 
by  the  treatment  with  perindopril:  up-regulation  by  19%  and  27%  for  eNOS 
protein  expression  (p=ns)  and  (p<0.05),  respectively,  was  observed.  This 
modulation  was  at  least  in  part  mediated  by  the  activation  of  bradykinin  B2 
receptors since the use of a specific B2 receptor antagonist, icatibant, conteracted 
the beneficial effect of perindopril. In addition, a correlation between increased 
plasma bradykinin levels and eNOS up-regulation, was noted. 
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Relaxin  has  previously  been  described  to  act  via  cAMP  in  animal  models. 
Braddon first described relaxin-induced cAMP changes in the mouse symphysis 
in 1978 (Braddon, 1978). The causal relation between relaxin exposure, cAMP 
rise  and  inhibition  of  spontaneous  contractile  activity  in  the  rat  uterus  was 
described back in 1980 (Sanborn et al, 1980). These observations were confirmed 
for human endometrial glandular cells (Chen et al, 1988) and human breast cells 
(Bigazzi et al, 1992). Cronin et al found that relaxin increases cAMP levels in 
cultured anterior pituitary cells (Cronin et al, 1987). Toth et al, investigated the 
effect of relaxin on the isolated perfused rat heart. A cAMP dependent protein 
kinase  inhibitor  (H-89)  was  found  to  substantially  reduce  the  ANP  secretory 
effect of relaxin (Toth et al, 1996). 
 
When Hsu and colleagues discovered the relaxin receptors in 2002, LGR7 and 
LGR8 (now renamed RXFP1 and RXFP2 respectively), they showed that these G 
protein  coupled  receptors  mediate  the  action  of  relaxin  through  an  cAMP 
dependent pathway (Hsu et al, 2002). 
 
The Ivell group suggest that activation of the relaxin receptor leads to tyrosine 
phosphorylation,  which, in  turn,  inhibits  phosphodiesterase  (PDE)  activity  and 
further  upregulates  cAMP  levels.  They  examined  human  endometrial  stromal 
cells and human macrophages (THP-1) in the human monocyte cell line to show 
that the relaxin receptor also initiates tyrosine kinase activation (Bartsch et al, 
2001, Ivell, 2002, Bartsch et al, 2004, Ivell et al, 2005).    174
 
Previously  we  showed  that  endothelial  denudation  greatly  reduced  the 
vasodilation action of relaxin in human small resistance arteries.  This observation 
was in keeping with a number of animal studies and a study in human vascular 
smooth muscle cells suggesting the action of relaxin involves nitric oxide-cGMP 
signalling.  In spite of this, neither inhibition of nitric oxide synthase with L-
NOARG, or with L-NAME, blocked the vasodilator effect of relaxin in this study, 
in patients treated with ACE inhibitors.  Direct inhibition of soluble guanylate 
cyclase with ODQ did, however, reduce the vasodilator action of relaxin, raising 
the possibility that relaxin causes NO-independent activation of soluble guanylate 
cyclase  in  these  patients.    In  keeping  with  this,  the  cGMP  phosphodiesterase 
inhibitor  zaprinast,  which  prevents  the  breakdown  of  cGMP,  augmented  the 
vasodilator effect of relaxin.   
 
Other groups have demonstrated that relaxin’s vasodilatory effect is mediated via 
more  than  one  distinct  pathway.  Longo  et  al,  studied  uterine  arteries  from 
pregnant rats and found that relaxin’s effect in these arteries was mediated by 
nitric  oxide,  soluble  guanylate  cyclase  (which  converts  GTP  to  cGMP)  and 
adenylate  cyclase  (which  is  responsible  for  the  production  of  cAMP).  They 
suggest  that  the  NO-cGMP  pathway  is  one  of  the  second  messenger  systems 
involved in the vascular effects of relaxin in pregnancy but that cAMP is also 
involved (Longo et al, 2003). 
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Putative  interactions  between  relaxin  receptor  signaling  and  the  intrinsic  NO 
pathway have been described (Nistri and Bani, 2003). See Figure 8.1 below. 
 
 
Figure  8.1    Possible  Interactions  Between  Relaxin  Receptor  and  NO 
Pathway. 
 
 
 
 
 
 
 
 
 
 
 
AC: adenylate cyclase, cAMP: cyclic adenosine monophosphate, cGMP: cyclic 
guanosine  monophosphate,  GC:  guanylate  cyclase,  Gs:  Gs  proteins,  GTP: 
guanosine triphosphate, IκB: inhibitor subunit of nuclear factor kappa-B, PKA: 
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protein  kinase,    NF-κB:  nuclear  factor  kappa-B,  NO:  nitric  oxide,  NOS  II: 
inducible NO synthase, NOS III: constitutive NO synthase, RLX: relaxin 
(Adapted from Nistri and Bani, 2003). 
 
 
 
Our studies have, however, by necessity been carried out in arteries from patients 
with  coronary  heart  disease  and  it  is  possible  that  the  balance  between  these 
vasodilator  mechanisms  could  be  different  in  healthy  controls.    Coats  et  al, 
showed  that  EDHF  is  the  major  contibutor  to  endothelium-dependent 
vasorelaxation in human subcutaneous resistance arteries in healthy volunteers 
(Coats et al, 2001).  We have been unable to confirm this as  a  mechanism of 
action for relaxin, in resistance arteries taken from patients with coronary artery 
disease. 
From  a  therapeutic  perspective,  however,  our  patient  group  is  relevant  and 
interesting.  The therapeutic potential of relaxin as a vasodilator is perhaps less 
than previously considered, given that so many patients with cardiac disease have 
an indication for treatment with an ACE inhibitor.   
 
Our results, however, open up another possible therapeutic avenue for relaxin.  
Type  5  phosphodiesterase  inhibitors  seem  to  have  limited  effectiveness  as  a 
treatment  for  erectile  dysfunction  in  certain  subsets  of  patients,  for  example 
diabetics,  probably  because  of  impaired  endogenous  NO  production.    177
Theoretically, NO-independent activators of guanylate cyclase (of which relaxin 
seems to be one) may be more effective. 
 
 
 
8.2.3 Summary 
 
In summary, we have shown that the vasodilator peptide relaxin acts differently in 
human  small  resistance  arteries  in  patients  treated  and  not  treated  with  ACE 
inhibitors.  In  ACEI-treated  patients,  relaxin  appears  to  work  via  two  distinct 
second messenger systems.  One pathway involves vasodilator prostanoids and 
cAMP. The other pathway may involve NO-independent activation of guanylate 
cyclase and cGMP.  
 
In non-ACEI-treated patients, relaxin works via an NO-dependent cGMP second 
messenger pathway. The other pathway involves vasodilator prostanoids but this 
does not appear to be as powerful as the cGMP pathway. 
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8.3  RELAXIN  IN  HUMAN  INTERNAL  MAMMARY  ARTERIES  AND 
SAPHENOUS VEINS 
 
Although, in small human systemic resistance arteries, we showed that relaxin is a 
potent vasodilator (Fisher et al, 2002), we were unable to find that in human large 
calibre vessels i.e. internal mammary arteries and long saphenous veins that relaxin 
had any vasodilator effect compared to control. 
 
8.3.1 Relaxin is Endothlium-Dependent 
 
We  know  that  relaxin  is  endothelium-dependent  and  it  proved  to  be  extremely 
difficult to obtain samples of IMA and LSV where the endothelium was indeed 
intact. Although for this set of experiments, only vessels where the endothelium 
had been found to be intact, were used in the data set, perhaps the endothelial 
function  of  the  vessels  was  impaired  and  this  had  an  impact  with  regard  to 
relaxin’s lack of action. Of course, relaxin may not act as a vasodilator of large 
calibre  vessels  and  certainly  Reid  et  al,  reported  that  relaxin  had  no  effect  on 
endothelium intact rat aortae pre-constricted with noradrenaline (Reid et al, 2001). 
Of course, there may also be marked species differences in the action of relaxin as 
documented with other peptides. Interestingly, Hillier et al, investigated the action 
in  humans,  of  the  peptide,  human  urotensin  II  (hUII)  which  is  a  potent 
vasoconstrictor in some fish and mammals (e.g. cynomolgus monkey). They found   179
that hUII had no vasoconstrictor action in human arteries and veins of different 
sizes and vascular beds showing a marked species difference (Hillier et al, 2001b). 
 
 
8.3.2 Relaxin and Arteries 
 
It  would  seem,  therefore,  that  relaxin  does  not  vasodilate  all  arteries.    Human 
relaxin did not dilate human myometrial and uteroplacental arteries pre-contracted 
with  norepinephrine,  endothelin  or  U46619  (Petersen  et  al,  1991).    Similarly, 
porcine  relaxin  has  no  effect  on  human  umbilical  arteries  pre-contracted  with 
potassium chloride or serotonin (Dombrowski et al, 1986).   This suggests that 
relaxin does not act as a vasodilator in the placental-fetal circulation.  We found 
that  relaxin  is  inert  in  preconstricted  human  pulmonary  resistance  arteries,  in 
contrast to systemic vessels (Fisher et al, 2002).  This may reflect differing relaxin 
receptor distribution in the circulation, as the nitric oxide vasodilator pathway was 
functionally intact in these pulmonary vessels (Bathgate et al, 2002). 
 
8.3.3. Relaxin and Veins 
 
There is very little reported in the literature regarding the action of relaxin on the 
venous  system.  Massicotte  et  al,  found  that  there  was  a  blunted  response  to 
vasoconstrictors,  arginine-vasopressin  and  norepinephrine  in  the  perfused 
mesenteric artery (with the concentration response curves shifted to the right by a   180
factor  of  two  (p<0.05  and  p<0.005  respectively)  after  treatment  with  relaxin. 
However, in the isolated portal vein, no statistical differences were observed in 
either  the  maximum  response  or  sensitivity  to  angiotensin  II  or  norepinephrine 
(Massicotte et al, 1989). 
 
8.3.4 Relaxin and ACE Inhibitors 
 
We reported that the vasodilatory effect of relaxin in patients treated with ACE 
inhibitors is significantly reduced. Of the ten patients whose IMA and LSV were 
harvested at the time of coronary artery bypass grafting, only 2 of them were on 
ACE inhibitors, so this is unlikely to be the cause of relaxin’s lack of effect in IMA 
and LSV.   
 
8.3.5 Relaxin and Beta-blockers 
 
There  has  been  very  little  reported  in  the  literature  on  the  interaction  of 
betablockers with relaxin. One in vivo study reported that treatment with the β-
adrenoreceptor antagonist propanolol significantly reduces the heart rate response 
to relaxin (Summerlee and Parry, 1993). In in vitro studies, propanolol has a small 
inhibitory action on the effects of relaxin in the heart (Kakouris et al, 1992). Of the 
10 patients whose IMA and LSV were used in the study, 8 of them were on beta-
blockers so this may have had an effect on relaxin in these vessels. Against this 
hypothesis however, is the fact that in our study on small resistance arteries where   181
relaxin was found to be a potent vasodilator, 11 out of 13 patients were on long 
term betablockers.  
 
 
8.3.6 Summary 
 
We have been unable to show that relaxin has a vasodilatory effect in human large 
calibre vessels, neither internal mammary arteries nor long saphenous veins. 
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8.4  RELAXIN  COMPARED  WITH  NT  pro  BNP  AS  A  PROGNOSTIC 
INDICATOR IN HEART FAILURE 
 
Our study confirms that heart failure due to left ventricular systolic dysfunction is 
associated  with  marked  elevation  of  the  plasma  concentration  of  the  two  new 
neurohumoral markers N-terminal pro BNP and relaxin.   
 
8.4.1 NT pro BNP in Heart Failure 
 
Prior to this study, there were few reports of plasma NT pro BNP levels in heart 
failure. Hobbs et al, investigated the performance of NT pro BNP in diagnosing 
heart  failure  in  various  randomly  selected  general  and  high  risk  community 
populations. They found that for NT pro BNP in the diagnosis of heart failure in 
the  general  population,  a  level  of  >36  pmol/l  had  a  sensitivity  of  100%,  a 
specificity of 70%, a positive predictive value of 7% and a negative predictive 
value of 100% (Hobbs et al, 2002). Masson et al compared BNP with NT pro BNP 
in ambulatory patients with heart failure and found that the concentration of both 
peptides increased in a similar fashion according to the severity of NYHA class, 
left ventricular ejection fraction, aetiology and age. They concluded that NT pro 
BNP correlates equally to BNP with clinical variables in patients with CHF. Hunt 
et al, also compared BNP with NT pro BNP in patients with heart failure. They 
noted  that  plasma  levels  of  NT  pro  BNP  are  raised  in  cardiac  impairment, 
including  NYHA  class  I  i.e.  asymptomatic  patients,  and  rise  with  cardiac   183
decompensation. They found that the proportional and absolute increment above 
normal levels of NT pro BNP exceeds that for BNP suggesting that NT pro BNP 
may be a more discerning marker of early cardiac dysfunction than BNP (Hunt et 
al, 1997). Talwar et al, found that NT pro BNP is a strong, independent predictor 
of left ventricular dysfunction demonstrating a linear relationship between NT pro 
BNP and left ventricular wall motion index. NT pro BNP had a sensitivity of 95% 
and  specificity  of  55%.  Of  more  clinical  importance,  they  felt,  was  the  high 
negative  predictive  value  of  93%  of  NT  pro  BNP  in  the  diagnosis  of  left 
ventricular dysfunction (Talwar et al,1999). 
 
 
8.4.2 Relaxin in Heart Failure 
 
At  the  time  of  this  study,  there  was  only  one  other  report  describing  relaxin 
concentrations in heart failure (Dschietzig et al, 2001).  
 
More recently, Kupari et al, investigated the role of relaxin in pressure overload-
induced  human  heart  failure.  They  studied  patients  undergoing  cardiac 
catheterisation for isolated aortic stenosis. Blood was sampled from the aortic root 
and from the coronary sinus. The concentration gradients of relaxin from the aortic 
root  to  the  coronary  sinus  indicated  relaxin  extraction  by  the  heart  in  control 
patients in keeping with the findings from our study (Fisher et al, 2003a) described 
in  Chapter  7.  In  patients  with  systolic  heart  failure  the  transcardiac  gradient   184
indicated relaxin production. However, this did not translate into elevated systemic 
concentrations. They conclude that relaxin is not a major player in human heart 
failure (Kupari et al, 2005). Kruger et al, investigated circulating relaxin and its 
potential role in stable CHF at rest and after physical exercise. They were unable to 
find a difference in relaxin plasma levels at rest and after exercise between patients 
with CHF and controls (Kruger et al, 2004). 
 
8.4.3 NT pro BNP as a Predictor of Outcome. 
 
In  this  study,  NT  pro  BNP  was  also  predictive  of  both  death  and  death  or 
readmission with worsening CHF.  Though the predictive value of other natriuretic 
peptides  in  CHF  has  been  extensively  reported  (Hall,  1994),  (Eriksson,  1995), 
(Dickstein, 1997), (Selvais, 2000), (McDonagh, 2001), (Bettenscourt, 2002), we 
know of only one other study (at the time of this study) describing the prognostic 
importance  of  NT  pro  BNP  in  CHF  (Richards,  2001).    In  a  sub-study  of  the 
Australia New Zealand carvedilol trial, Richards et al found that NT pro BNP was 
a strong predictor of all cause mortality as well as admission to hospital with CHF.  
In that study, NT pro BNP had more predictive power for these outcomes than left 
ventricular ejection fraction.  We also found NT-pro BNP to be an independent 
predictor of adverse clinical outcome.  Consequently, there are now two studies 
confirming that this very stable peptide (Hughes et al, 1999), (Downie et al, 1999), 
which is easy to assay (Hunt et al, 1997), (Hughes et al, 1999), (Downie et al, 
1999), has prognostic as well as diagnostic value in CHF.  Since publishing our   185
data (Fisher et al, 2003b), there have been numerous studies published showing the 
predictive value of NT pro BNP in heart failure prognosis (Hartmann et al, 2004), 
(Groenning et al, 2004), (Kirk et al, 2004), (Squire et al, 2004). 
 
NT pro BNP also gives prognostic information after myocardial infarction and in 
acute coronary syndromes (Richards et al, 1998), (Omland et al, 2002). Richards et 
al, found that plasma NT pro BNP levels measured 2 to 4 days after myocardial 
infarction  independently  predicted  left  ventricular  function  and  2-year  survival. 
They conclude that stratification of patients into low and high risk groups could be 
facilitated by NT pro BNP measurements. 
 
Recently, NT pro BNP has been shown to be an independent prognostic marker in 
severe  sepsis  and  septic  shock  (Varpula  et  al,  2007);  infective  endocarditis 
(Kahveci et al, 2007); after vascular surgery (Mahla  et al, 2007) and in stable 
coronary artery disease (Omland et al, 2007). 
 
8.4.4 Summary 
 
Dschietzig et al have recently shown that cardiac relaxin production and plasma 
relaxin concentrations are increased in CHF, the latter finding confirmed in the 
present  study  (Dschietzig  et  al,  2001).    As  relaxin  is  a  powerful  vasodilator 
secreted  by  the  heart  (Fisher  et  al,  2002),  our  hypothesis  was  that  like  the   186
natriuretic peptides, plasma concentrations might be related to prognosis.  We were 
not able to confirm this. 
The timing of blood samples may be relevant. Blood samples were taken from 
CHF patients prior to discharge i.e. once stable. Perhaps if the sampling had been 
done on admission (when the patient was in acute heart failure) we may have been 
able to show relaxin concentrations related to prognosis. 
Though  plasma  concentrations  of  most  neurohumoral  factors  are  predictive  of 
outcome, not all are (e.g. arginine vasopressin) (Richards et al, 1998).  We were 
unable  to  show  any  correlation  between  plasma  NT  pro  BNP  and  relaxin 
concentrations suggesting different release mechanisms.  The atria may be a more 
important source of relaxin than the ventricles, whereas the opposite is true for NT 
pro BNP (Dschietzig et al, 2001), (Taylor et al, 1994).  As a biochemical marker of 
left ventricular dilatation and wall stress, it is perhaps not surprising, therefore, that 
NT pro BNP is a powerful prognostic factor (Richards et al, 2001).  Furthermore, 
net cardiac relaxin release is not pronounced except in moderate to severe CHF and 
even then is not always observed.  These reasons may explain why relaxin was not 
predictive of outcome.  However, it remains possible that relaxin does have some 
weak predictive effect which was not revealed because of the modest size of our 
study.  
 
In  summary,  even  though  relaxin  has  been  shown  to  be  a  potent  vasodilator 
released by the failing heart, it is not a powerful prognostic indicator in CHF. 
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8.5  TRANSCARDIAC  AND  TRANSPULMONARY  GRADIENTS  OF 
RELAXIN 
 
Dschietzig  et  al  showed  higher  coronary  sinus  than  left  ventricular  relaxin 
concentrations in 11 of 14 patients with severe CHF, suggesting that the failing 
heart may be a source of circulating relaxin (Dschietzig et al, 2001).  We found the 
opposite across the non-failing heart i.e. net extraction of relaxin. Kupari et al, have 
since confirmed this finding in patients without heart failure (Kupari et al, 2005). 
Further inspection of the data from Dschietzig et al shows no trans-cardiac gradient 
in patients with moderate CHF and an aorta-coronary sinus decrement in controls, 
in  keeping  with  our  findings  (Dschietzig  et  al,  2001).    This  suggests  that  the 
contribution of the heart to circulating relaxin varies according to the presence or 
absence  of  CHF.    Whether  it  is  left  ventricular  systolic  dysfunction,  abnormal 
pulmonary or systemic haemodynamics, neurohumoral activation or other factors 
that leads to net cardiac secretion of relaxin in CHF is presently unknown.  
 
The pattern of relaxin secretion/extraction is distinct from other hormones.  A-type 
and B-type natriuretic peptide increase from aorta to coronary sinus in both the 
non-failing and failing heart (more markedly in the latter) (Northridge et al, 1992). 
Adrenomedullin  is  also  secreted  by  both  the  failing  and  non-failing  heart.  In 
contrast, endothelin-1 is extracted by the failing heart, whereas there seems to be 
either  no  trans-cardiac  gradient  or higher coronary  sinus  concentrations  in  non-
failing  hearts  (Stangl  et  al,  2000).  There  is  no  trans-cardiac  gradient  in  plasma   188
aldosterone  concentration  in  the  non-failing  heart  but  an  increment  in  coronary 
sinus aldosterone concentration in CHF. 
 
Interpretation of the cardiac extraction of relaxin by the normal heart, compared to 
its secretion by the failing heart, is difficult.  The mechanisms of relaxin clearance 
from the circulation are unknown.  Changes in the trans-cardiac concentration of 
other peptides seem to reflect changes in receptor density/affinity e.g. decreases in 
endothelin  concentration  across  the  failing  heart  are  probably  caused  by  the 
increase in myocardial ETA and ETB (Stangl et al, 2000).  The receptors for relaxin 
have only recently been described and nothing is known about the effect of CHF on 
their expression (Dschietzig et al, 2001). 
 
The  transpulmonary  gradient  in  relaxin  concentration  has  not  been  described 
before.  Neither net extraction nor secretion occurred, which is different than for 
other  peptides.    Pulmonary  extraction  of  ANP  (Northridge  et  al,  1992)  and 
adrenomedullin  has  been  described.    For  endothelin,  some  have  described  no 
transpulmonary concentration gradient, others pulmonary extraction and others still 
that both secretion and extraction, which balance each other out, occur (Stangl et al, 
2000).    Relaxin  also  differs  from  other  peptides  in  having  no  effect  in  small 
pulmonary  resistance  arteries  (whereas  it  is  a  potent  vasodilator  in  comparable 
vessels from the systemic circulation) (Fisher et al, 2002). 
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In summary, in patients with coronary disease but without CHF, there is net cardiac 
extraction of relaxin in contrast to reported secretion in CHF.  In patients without 
CHF there is no transpulmonary gradient in relaxin. 
 
 
 
8.6 LIMITATIONS OF RESEARCH 
 
8.6.1 Subjects studied 
 
On determining the comparative potency of relaxin and its mechanism of action, 
patients  with coronary  artery  disease  generously  provided  buttock  biopsies  as  a 
source of small resistance arteries. In addition to this, it would have been useful to 
have had similar samples from healthy volunteers to determine the comparative 
potency and mechanism of action of relaxin in these subjects. 
Also, the patients that had buttock biopsies taken, had coronary artery disease but 
were not known to have heart failure and it would have been interesting to see if 
relaxin’s  comparative  potency  and  mechanism  of action  differs  in  patients  with 
heart failure. 
 
 
 
   190
8.6.2 In Vivo Studies 
 
We had hoped as part of my MD thesis to perform in vivo studies of the action of 
relaxin  in  human  resistance  arteries  with  plasma  concentrations  reflecting  the 
physiological and pathophysiological range. This would have involved 1) dorsal 
hand vein studies, using a modified Aellig technique, to document the local effect 
of  relaxin  in  a  human  dorsal  hand  vein  and  2)  forearm  venous  occlusion 
plethysmography to study the local arterial effect of relaxin in the human brachial 
artery. 
Unfortunately, Connectics Corporation who kindly gifted the relaxin for use in my 
ex vivo experiments, would not allow in vivo studies using relaxin gifted by them to 
be performed in humans. 
 
 
 
8.7 FUTURE RESEARCH 
 
The field of relaxin research is progressing rapidly. A single site open-label study 
of  relaxin  in  patients  with  compensated  CHF  has  recently  been  completed  in 
Germany  (Dschietzig  et  al,  2009).  This  was  a  safety  and  dose-finding  study  of 
intravenous relaxin given for 24 hours at doses ranging from 10 to 960 µg/kg/day. 
Pharmacodynamic dose-response parameters (serial haemodynamic measurements 
using  pulmonary  artery  and  radial  artery  catheters  and  serial  renal  chemistry   191
parameters) were evaluated to define relaxin doses for  further study. The study 
enrolled 16 subjects with compensated CHF, NYHA class II-III due to ischaemic 
heart  disease,  hypertensive  heart  disease  or  dilated  cardiomyopathy  with  keft 
ventricular ejection fraction <35%, pulmonary capillary wedge pressure (PCWP) > 
16mmHg and cardiac index <  2.5 l/min/m
2. All 16 subjects completed dosing and 
the day 9 follow-up visit. Relaxin was safe and well-tolerated in all subjects. Doses 
of relaxin in the range of 10-100 µg/kg/day appeared to have a more pronounced 
effect than higher doses on right atrial pressure, pulmonary artery pressure, PCWP 
and NT pro-BNP while higher doses in the range of 240-960 µg/kg/day tended to 
have a greater effect on CI. Values for systemic vascular resistance decreased at all 
doses. The different dose responses observed may be explained by imbalances in 
baseline  haemodynamic  status  of  the  dose  groups  or  may  be  due  to  random 
variability in a small pilot study. However, the effect of relaxin may follow a U-
shaped dose-response curve.  
A high proportion of patients with acute heart failure have elevated blood pressure 
at the time of presentation, so called acute vascular failure (Teichman et al, 2008). 
Renal dysfunction is a common co-morbidity and major predictor of poor outcomes 
in  patients  with  acute  heart  failure  and  appears  to  be  particularly  common  in 
patients with acute vascular failure. Currently, no therapy has been demonstrated to 
improve  symptoms  or  renal  function  in  this  group  of  patients.  The  current 
understanding of the haemodynamic and renovascular effects of relaxin, as well as 
the encouraging results from the evaluation of relaxin in patients with compensated 
heart failure, support the investigation of the use of relaxin as a therapeutic agent   192
for the treatment of patients with acute vascular failure. The RELAX-AHF study 
has been undertaken to evaluate the effects of relaxin therapy on symptoms, signs 
and outcomes in these patients and its results are eagerly awaited. 
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